Dihydropyrazolopyrazinone derivatives with MGAT2 inhibitory activity

Abstract

The present invention provides a compound represented by the formula: (In the formula, R 1 is hydrogen, hydroxy, etc.; R 2a and R 2b may be taken together with the adjacent carbon atom to form ring B, Ring B is a substituted or unsubstituted non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring; R 3a is hydrogen, halogen, hydroxy, etc.; R 3b is hydrogen, halogen, hydroxy, etc.; R 4a is the expression: and; L 3 is a single bond or a substituted or unsubstituted alkylene; R 7 is hydrogen, halogen, hydroxy, etc. R 4b is halogen, cyano, carboxy, etc.), or a pharmaceutically acceptable salt thereof.

Description

[Technical field]

[0001] The present invention relates to a compound having an inhibitory effect on monoacylglycerol acyltransferase 2 (hereinafter also referred to as MGAT2), or a pharma- ceutically acceptable salt thereof, and a pharmaceutical composition containing the same. [Background technology]

[0002] Obesity is defined as the accumulation of excess fat or adipose tissue in the body relative to lean body mass and is recognized as a major risk factor for health problems. Body Mass Index (BMI) is a simple index of weight-to-height ratio commonly used to classify adult (age 15 and over) populations or individuals as overweight or obese. It is calculated as body weight in kilograms divided by height in metres squared (kg / m 2 The World Health Organization defines a BMI of 25 kg / m 2 Overweight: 30kg / m 2 The Japan Society for the Study of Obesity defines a BMI of 25 kg / m 2 The above is considered "obesity". Because the number of obesity-related diseases, including diabetes and dyslipidemia, increases with BMI, and the average number of diseases increases with a BMI of 25 kg / m2. 2 This is because the ratio is greater than 1.0. According to a 2005 survey by the World Health Organization, approximately 1.6 billion people worldwide are overweight and at least 400 million are obese. Obesity is mainly caused by an increase in the ratio of calorie intake to expenditure in physical activity and daily life. The number of obese people has increased in recent years due to the increase in the intake of high-fat and high-sugar foods, and it is expected that more than 700 million people will be diagnosed with obesity worldwide in 2015. Treatments for these conditions include dietary therapy, exercise therapy, and drug therapy. Drugs such as orlistat, mazindol, and sibutramine are used in drug therapy, but none are satisfactory in terms of both efficacy and side effects. Excessive intake of neutral fats is one of the causes of obesity. Neutral fats (triglycerols) ingested through meals are broken down into 2-monoacylglycerol and free fatty acids by pancreatic lipase in the digestive tract, and are absorbed by small intestinal epithelial cells. The acyl group of the free fatty acid is transferred to 2-monoacylglycerol by monoacylglycerol acyltransferase (MGAT). The resulting diacylglycerol is further converted to neutral fats by diacylglycerol acyltransferase (DGAT). Three isoforms of MGAT, MGAT1, MGAT2, and MGAT3, have been identified. Of these, MGAT2 and MGAT3 are highly expressed in the small intestine and are thought to be involved in fat absorption in the small intestine. It has been reported that, in an experiment using MGAT2 knockout mice, high-fat diet loading enhances MGAT2 expression in the small intestine and increases MGAT activity (Non-Patent Document 1).Furthermore, in MGAT2 knockout mice, suppression of weight gain, insulin resistance induction, blood cholesterol increase, fatty liver formation, etc., and enhancement of energy consumption due to high-fat diet loading have been confirmed (Non-Patent Document 2). Although compounds having MGAT2 inhibitory activity have been reported so far (Patent Documents 1 to 19, Non-Patent Documents 3 to 13), the compound of the present invention shown below has not been disclosed. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] International Publication No. 2010 / 095767 [Patent Document 2] International Publication No. 2012 / 091010 [Patent Document 3] International Publication No. 2012 / 124744 [Patent Document 4] International Publication No. 2013 / 082345 [Patent Document 5] International Publication No. 2013 / 112323 [Patent Document 6] International Publication No. 2013 / 116065 [Patent Document 7] International Publication No. 2013 / 116075 [Patent Document 8] International Publication No. 2014 / 074365 [Patent Document 9] International Publication No. 2014 / 133134 [Patent Document 10] International Publication No. 2014 / 193884 [Patent Document 11] Patent Publication No. 2014-5245 [Patent Document 12] Patent Publication No. 2014-9165 [Patent Document 13] International Publication No. 2015 / 112465 [Patent Document 14] International Publication No. 2015 / 129845 [Patent Document 15] International Publication No. 2015 / 134699 [Patent Document 16] International Publication No. 2015 / 134701 [Patent Document 17] International Publication No. 2015 / 191681 [Patent Document 18] International Publication No. 2016 / 121782 [Patent Document 19] International Publication No. 2017 / 069224 [Non-patent literature]

[0004] [Non-Patent Document 1] Journal of Biological Chemistry (2004), 279, 18878-18886 [Non-Patent Document 2] Nature Medicine (2009), 15, (4), 442-446 [Non-Patent Document 3] Bioorganic & Medicinal Chemistry Letter (2013), 23, 2721-2726 [Non-Patent Document 4] Med. Chem. Commun (2013), 4, 1305-1311 [Non-Patent Document 5] Bioorganic & Medicinal Chemistry Letter (2015), 23, 5922-5931 [Non-Patent Document 6] Bioorganic & Medicinal Chemistry Letter (2015), 23, 4544-4560 [Non-Patent Document 7] Journal of Lipid Research 2015, 56, 747-753 [Non-Patent Document 8] European Journal of Pharmacology, 2015, 758, 72-81 [Non-Patent Document 9] Journal of Medicinal Chemistry (2015), 58, 3892-3909 [Non-Patent Document 10] HETEROCYCLES 2016, 92, 470-484 [Non-Patent Document 11] Chemical and Pharmaceutical Bulletin, 2016, 64, 228-238 [Non-Patent Document 12] European Journal of Pharmacology, 2016, 791, 569-577 [Non-Patent Document 13] Analytical Biochemistry, 2016, 501, 48-55 Summary of the Invention [Problem to be solved by the invention]

[0005] An object of the present invention is to provide a compound having an MGAT2 inhibitory activity or a pharma- ceutically acceptable salt thereof, and a pharmaceutical composition containing the compound or the salt. [Means for solving the problem]

[0006] As a result of intensive research, the present inventors have succeeded in synthesizing an excellent compound having an MGAT2 inhibitory effect.

[0007] [1] Formula (I): [ka] (In the formula, R 1 is hydrogen, hydroxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted substituted or unsubstituted non-aromatic heterocycle carbonyl, substituted or unsubstituted aromatic carbocycle oxycarbonyl, substituted or unsubstituted non-aromatic carbocycle oxycarbonyl, substituted or unsubstituted aromatic heterocycle oxycarbonyl, substituted or unsubstituted non-aromatic heterocycle oxycarbonyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, or substituted or unsubstituted non-aromatic heterocycle sulfonyl; R 2a is the expression: [ka] (wherein ring C is an aromatic carbocycle, an aromatic heterocycle, a non-aromatic carbocycle, or a non-aromatic heterocycle; R 5each independently represents halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyl, Oxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, is an unsubstituted aromatic carbocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted aromatic carbocycle-oxy, a substituted or unsubstituted non-aromatic carbocycle-oxy, a substituted or unsubstituted aromatic heterocycle-oxy, a substituted or unsubstituted non-aromatic heterocycle-oxy, a substituted or unsubstituted aromatic carbocycle-carbonyloxy, a substituted or unsubstituted non-aromatic carbocycle-carbonyloxy, a substituted or unsubstituted aromatic heterocycle-carbonyloxy, a substituted or unsubstituted non-aromatic heterocycle carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl,Substituted or unsubstituted aromatic heterocycle sulfanyl, substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -LN=S(=O)(-R, S1 )-R S2 , formula:-LS(=O)(=NR N )-R S1 , formula:-N=S(=NR N )(-R S1 )-R S2 , or the formula: -S(=NR N )2-R S1 is a group represented by m is an integer from 1 to 5; R 2b is hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted alkylsulfonyl; or R 2a and R 2b may be taken together with the adjacent carbon atom to form ring B, Ring B is a substituted or unsubstituted non-aromatic carbocycle or a substituted or unsubstituted non-aromatic heterocycle; R 3ais hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic group-oxy, substituted or unsubstituted non-aromatic carbocyclic group-oxy, substituted or unsubstituted aromatic heterocyclic group-oxy, substituted or unsubstituted non-aromatic heterocyclic group-oxy, substituted or unsubstituted aromatic carbocyclic group-sulfonyl, substituted or unsubstituted non-aromatic carbocyclic group-sulfonyl, substituted or unsubstituted aromatic heterocyclic group-sulfonyl, or substituted or unsubstituted non-aromatic heterocyclic group-sulfonyl; R 3b is hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic group-oxy, substituted or unsubstituted non-aromatic carbocyclic group-oxy, substituted or unsubstituted aromatic heterocyclic group-oxy, substituted or unsubstituted non-aromatic heterocyclic group-oxy, substituted or unsubstituted aromatic carbocyclic group-sulfonyl, substituted or unsubstituted non-aromatic carbocyclic group-sulfonyl, substituted or unsubstituted aromatic heterocyclic group-sulfonyl, or substituted or unsubstituted non-aromatic heterocyclic group-sulfonyl; R 3a and R 3b may, together with adjacent carbon atoms, form a substituted or unsubstituted non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring; or R 2b and R 3b may, together with adjacent carbon atoms, form a substituted or unsubstituted non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring; R 4a is the expression: [ka] and; L 3 is a single bond or a substituted or unsubstituted alkylene; R 7is hydrogen, halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbo nyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic ring-oxy, substituted or unsubstituted non-aromatic carbocyclic ring-oxy, substituted or unsubstituted aromatic heterocyclic ring-oxy, substituted or unsubstituted non-aromatic heterocyclic ring-oxy, substituted or unsubstituted aromatic carbocyclic ring-carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic ring-carbonyloxy, substituted or unsubstituted aromatic heterocyclic ring-carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic ring-carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl, substituted or unsubstituted aromatic heterocyclic sulfanyl,Substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -LN=S(=O)(-R, S1 )-R S2 , formula:-LS(=O)(=NR N )-R S1 , formula:-N=S(=NR N )(-R S1 )-R S2 , or the formula: -S(=NR N )2-R S1 is a group represented by However, L 3 If is a single bond, R 7 is not hydrogen or a halogen, R 4bis halogen, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkene, nylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic groups, substituted or unsubstituted is an unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted aromatic carbocyclic ring-oxy, a substituted or unsubstituted non-aromatic carbocyclic ring-oxy, a substituted or unsubstituted aromatic heterocyclic ring-oxy, a substituted or unsubstituted non-aromatic heterocyclic ring-oxy, a substituted or unsubstituted aromatic carbocyclic ring-carbonyloxy, a substituted or unsubstituted non-aromatic carbocyclic ring-carbonyloxy, a substituted or unsubstituted aromatic heterocyclic ring-carbonyloxy, a substituted or unsubstituted non-aromatic heterocyclic ring-carbonyloxy, a substituted or unsubstituted aromatic aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl, substituted or unsubstituted aromatic heterocyclic sulfanyl,Substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -LN=S(=O)(-R, S1 )-R S2 , formula:-LS(=O)(=NR N )-R S1 , formula:-N=S(=NR N )(-R S1 )-R S2 , or the formula: -S(=NR N )2-R S1 is a group represented by Each L is independently a single bond, alkylene, or C(=O); R S1 and R S2 are each independently hydrogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted aromatic carbocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted non-aromatic heterocyclic group; or R attached to the same sulfur atom S1 and R S2 may be combined with the sulfur atom to form a substituted or unsubstituted non-aromatic heterocycle; R Nare each independently hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, or substituted or unsubstituted non-aromatic heterocyclic carbonyl), or a pharma- ceutically acceptable salt thereof. [2] The compound according to the above [1], wherein ring B is represented by any one of the following formulas, or a pharma- ceutically acceptable salt thereof. formula: [ka] (In the formula, B 1 CR 11a R 11b , N.R. 11c , O, or S; B 2 CR 12a R 12b , N.R. 12c , O, or S; B 3 CR 13a R 13b , N.R. 13c , O, or S; B 4 CR 14a R 14b , N.R. 14c , O, or S, and B 5 CR 15a R 15b , N.R. 15c , O, or S; R 11a , R 12a , R 13a , R 14a , and R 15aeach independently represents hydrogen, halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbo nyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocycle-oxy, substituted or unsubstituted non-aromatic carbocycle-oxy, substituted or unsubstituted aromatic heterocycle-oxy, substituted or unsubstituted non-aromatic heterocycle-oxy, substituted or unsubstituted aromatic carbocycle-carbonyloxy, substituted or unsubstituted non-aromatic carbocycle-carbonyloxy, substituted or unsubstituted aromatic heterocycle-carbonyloxy, substituted or unsubstituted non-aromatic heterocycle ring carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl,Substituted or unsubstituted aromatic heterocycle sulfanyl, substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -LN=S(=O)(-R, S1 )-R S2 , formula:-LS(=O)(=NR N )-R S1 , formula:-N=S(=NR N )(-R S1 )-R S2 , or the formula: -S(=NR N )2-R S1 is a group represented by R 11b , R 12b , R 13b , R 14b , and R 15beach independently represents hydrogen, halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbo nyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocycle-oxy, substituted or unsubstituted non-aromatic carbocycle-oxy, substituted or unsubstituted aromatic heterocycle-oxy, substituted or unsubstituted non-aromatic heterocycle-oxy, substituted or unsubstituted aromatic carbocycle-carbonyloxy, substituted or unsubstituted non-aromatic carbocycle-carbonyloxy, substituted or unsubstituted aromatic heterocycle-carbonyloxy, substituted or unsubstituted non-aromatic heterocycle ring carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl,Substituted or unsubstituted aromatic heterocycle sulfanyl, substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -LN=S(=O)(-R, S1 )-R S2 , formula:-LS(=O)(=NR N )-R S1 , formula:-N=S(=NR N )(-R S1 )-R S2 , or the formula: -S(=NR N )2-R S1 is a group represented by R 11c , R 12c , R 13c , R 14c , and R 15ceach independently represents hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkene, nylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic groups, substituted or unsubstituted non-aromatic carbocyclic groups, substituted or unsubstituted aromatic heterocyclic groups, substituted or unsubstituted substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocycle-oxy, substituted or unsubstituted non-aromatic carbocycle-oxy, substituted or unsubstituted aromatic heterocycle-oxy, substituted or unsubstituted non-aromatic heterocycle-oxy, substituted or unsubstituted aromatic carbocycle-carbonyl, substituted or unsubstituted non-aromatic carbocycle-carbonyl, substituted or unsubstituted aromatic heterocycle-carbonyl, substituted or unsubstituted non-aromatic heterocycle-carbonyl, substituted or unsubstituted aromatic carbocycle-oxycarbonyl, substituted or unsubstituted non-aromatic carbocycle-oxycarbonyl, substituted or unsubstituted aromatic heterocycle-oxycarbonyl, substituted or unsubstituted non-aromatic heterocycle-oxycarbonyl, substituted or unsubstituted aromatic carbocycle-sulfanyl, substituted or unsubstituted non-aromatic carbocycle-sulfanyl, substituted or unsubstituted aromatic heterocycle-sulfanyl, substituted or unsubstituted non-aromatic heterocycle-sulfanyl, substituted or unsubstituted aromatic carbocycle-sulfinyl, substituted or unsubstituted non-aromatic carbocycle-sulfinyl, substituted or unsubstituted aromatic heterocycle-sulfinyl, substituted or unsubstituted non-aromatic heterocycle-sulfinyl, substituted or unsubstituted aromatic carbocycle-sulfonyl,a substituted or unsubstituted non-aromatic carbocyclic sulfonyl, a substituted or unsubstituted aromatic heterocyclic sulfonyl, or a substituted or unsubstituted non-aromatic heterocyclic sulfonyl; Or, R 11a and R 12a , R 12a and R 13a , R 13a and R 14a , and / or R 14a and R 15a may, together with adjacent carbon atoms, form a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted non-aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle, or a substituted or unsubstituted non-aromatic heterocycle; and / or R 11c and R 12a , R 11c and R 12c , R 12c and R 11a , R 12c and R 13a , R 12c and R 13c , R 13c and R 12a , R 13c and R 14a , R 13c and R 14c , R 14c and R 13a , R 14c and R 15a , R 14c and R 15c , and / or R 15c and R 14a may be taken together with adjacent atoms to form a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle; and / or R 11a and R 13a , R 11a and R 13c , R 11a and R 14a , R 11a and R 14c , R 11a and R 15a , R 11a and R 15c , R 11c and R 13a , R11c and R 13c , R 11c and R 14a , R 11c and R 14c , R 11c and R 15a , R 11c and R 15c , R 12a and R 14a , R 12a and R 14c , R 12a and R 15a , R 12a and R 15c , R 12c and R 14a , R 12c and R 14c , R 12c and R 15a , R 12c and R 15c , R 13a and R 15a , R 13a and R 15c , R 13c and R 15a , and / or R 13c and R 15c may be taken together to form a C2-C4 bridge, optionally interrupted by a heteroatom; and / or R 11b and R 12b , R 11b and R 12c , R 11c and R 12b , R 11c and R 12c , R 12b and R 13b , R 12b and R 13c , R 12c and R 13b , R 12c and R 13c , R 13b and R 14b , R 13b and R 14c , R 13c and R 14b , R 13c and R 14c , R 14b and R 15b , R 14b and R 15c , R14c and R 15b , and / or R 14c and R 15c may be taken together to form a bond, The other symbols are as defined above in [1].) [3] The compound according to the above [1] or [2], wherein ring B is represented by any one of the following formulas, or a pharma- ceutically acceptable salt thereof. formula: [ka] (In the formula, B 1 , C, CR 11a , or N, B 2 , C, CR 12a or N, B 3 CR 13a R 13b , N.R. 13c , O or S; B 4 CR 14a R 14b , N.R. 14c , O or S; B 5 CR 15a R 15b , N.R. 15c , O or S; R 11a , R 12a , R 13a , R 14a , and R 15aeach independently represents hydrogen, halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbo nyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocycle-oxy, substituted or unsubstituted non-aromatic carbocycle-oxy, substituted or unsubstituted aromatic heterocycle-oxy, substituted or unsubstituted non-aromatic heterocycle-oxy, substituted or unsubstituted aromatic carbocycle-carbonyloxy, substituted or unsubstituted non-aromatic carbocycle-carbonyloxy, substituted or unsubstituted aromatic heterocycle-carbonyloxy, substituted or unsubstituted non-aromatic heterocycle ring carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl,Substituted or unsubstituted aromatic heterocycle sulfanyl, substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -LN=S(=O)(-R, S1 )-R S2 , formula:-LS(=O)(=NR N )-R S1 , formula:-N=S(=NR N )(-R S1 )-R S2 , or the formula: -S(=NR N )2-R S1 is a group represented by R 13b , R 14b , and R 15beach independently represents hydrogen, halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbo nyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocycle-oxy, substituted or unsubstituted non-aromatic carbocycle-oxy, substituted or unsubstituted aromatic heterocycle-oxy, substituted or unsubstituted non-aromatic heterocycle-oxy, substituted or unsubstituted aromatic carbocycle-carbonyloxy, substituted or unsubstituted non-aromatic carbocycle-carbonyloxy, substituted or unsubstituted aromatic heterocycle-carbonyloxy, substituted or unsubstituted non-aromatic heterocycle ring carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl,Substituted or unsubstituted aromatic heterocycle sulfanyl, substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -LN=S(=O)(-R, S1 )-R S2 , formula:-LS(=O)(=NR N )-R S1 , formula:-N=S(=NR N )(-R S1 )-R S2 , or the formula: -S(=NR N )2-R S1 is a group represented by R 13c , R 14c , and R 15ceach independently represents hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkene, nylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic groups, substituted or unsubstituted non-aromatic carbocyclic groups, substituted or unsubstituted aromatic heterocyclic groups, substituted or unsubstituted substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocycle-oxy, substituted or unsubstituted non-aromatic carbocycle-oxy, substituted or unsubstituted aromatic heterocycle-oxy, substituted or unsubstituted non-aromatic heterocycle-oxy, substituted or unsubstituted aromatic carbocycle-carbonyl, substituted or unsubstituted non-aromatic carbocycle-carbonyl, substituted or unsubstituted aromatic heterocycle-carbonyl, substituted or unsubstituted non-aromatic heterocycle-carbonyl, substituted or unsubstituted aromatic carbocycle-oxycarbonyl, substituted or unsubstituted non-aromatic carbocycle-oxycarbonyl, substituted or unsubstituted aromatic heterocycle-oxycarbonyl, substituted or unsubstituted non-aromatic heterocycle-oxycarbonyl, substituted or unsubstituted aromatic carbocycle-sulfanyl, substituted or unsubstituted non-aromatic carbocycle-sulfanyl, substituted or unsubstituted aromatic heterocycle-sulfanyl, substituted or unsubstituted non-aromatic heterocycle-sulfanyl, substituted or unsubstituted aromatic carbocycle-sulfinyl, substituted or unsubstituted non-aromatic carbocycle-sulfinyl, substituted or unsubstituted aromatic heterocycle-sulfinyl, substituted or unsubstituted non-aromatic heterocycle-sulfinyl, substituted or unsubstituted aromatic carbocycle-sulfonyl,a substituted or unsubstituted non-aromatic carbocyclic sulfonyl, a substituted or unsubstituted aromatic heterocyclic sulfonyl, or a substituted or unsubstituted non-aromatic heterocyclic sulfonyl; Or, R 11a and R 13a , R 11a and R 13c , R 11a and R 14a , R 11a and R 14c , R 11a and R 15a , R 11a and R 15c , R 12a and R 14a , R 12a and R 14c , R 12a and R 15a , R 12a and R 15c , R 13a and R 15a , R 13a and R 15c , R 13c and R 15a , and / or R 13c and R 15c may be taken together to form a C2-C4 bridge, optionally interrupted by a heteroatom; and / or R 11a and R 12a , R 12a and R 13b , R 12a and R 13c , R 13b and R 14b , R 13b and R 14c , R 13c and R 14b , R 13c and R 14c , R 14b and R 15b , R 14b and R 15c , R 14c and R 15b , and / or R 14c and R 15c may be taken together to form a bond, Ring D is an aromatic carbocycle, a non-aromatic carbocycle, an aromatic heterocycle, or a non-aromatic heterocycle; R6each independently represents halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyl, Oxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, is an unsubstituted aromatic carbocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted aromatic carbocycle-oxy, a substituted or unsubstituted non-aromatic carbocycle-oxy, a substituted or unsubstituted aromatic heterocycle-oxy, a substituted or unsubstituted non-aromatic heterocycle-oxy, a substituted or unsubstituted aromatic carbocycle-carbonyloxy, a substituted or unsubstituted non-aromatic carbocycle-carbonyloxy, a substituted or unsubstituted aromatic heterocycle-carbonyloxy, a substituted or unsubstituted non-aromatic heterocycle carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl,Substituted or unsubstituted aromatic heterocycle sulfanyl, substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -LN=S(=O)(-R, S1 )-R S2 , formula:-LS(=O)(=NR N )-R S1 , formula:-N=S(=NR N )(-R S1 )-R S2 , or the formula: -S(=NR N )2-R S1 is a group represented by n is an integer from 1 to 4, The other symbols are as defined above in [1].) [4] The compound according to any one of the above [1] to [3], wherein ring B is represented by any one of the following formulas, or a pharma- ceutically acceptable salt thereof. formula: [ka] (In the formula, B 3 , B 4 , B 5 , R 6 and n is as defined above in [3]. [5] The compound according to any one of the above [1] to [4], wherein ring B is represented by any one of the following formulas, or a pharma- ceutically acceptable salt thereof. formula: [ka] (In the formula, R 6 , R 13a , R 13b , R 14a , R14b , R 15a , R 15b and n are as defined above in [3]. [6] R 6 are each independently halogen, cyano, hydroxy, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted non-aromatic carbocyclic oxy, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted non-aromatic carbocyclic sulfonyl, or substituted or unsubstituted non-aromatic heterocyclic sulfonyl, or a pharma- ceutically acceptable salt thereof. [7] R 6 are each independently a halogen, or a substituted or unsubstituted alkyloxy, or a pharma- ceutically acceptable salt thereof. [8] The compound according to any one of the above [3] to [5], wherein ring B is represented by any one of the following formulas, or a pharma- ceutically acceptable salt thereof. formula: [ka] (In the formula, R 6 are each independently substituted or unsubstituted alkyloxy; R 13a , R 13b , R 14a , R 14b , R 15a , and R 15b is the same as [3] above) [9] The compound according to any one of the above [3] to [5], wherein ring B is represented by any one of the following formulas, or a pharma- ceutically acceptable salt thereof. formula: [ka] (In the formula, R 6 are each independently a halogen or a substituted or unsubstituted alkyloxy; R 13a , R 13b , R 14a , R 14b , R 15a , and R 15b is the same as [3] above)

[10] The compound according to the above-mentioned [1], or a pharma- ceutically acceptable salt thereof, wherein ring C is an aromatic carbocycle or an aromatic heterocycle.

[11] R 5 are each independently halogen, cyano, hydroxy, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted non-aromatic carbocycleoxy, substituted or unsubstituted non-aromatic heterocycleoxy, substituted or unsubstituted non-aromatic carbocyclesulfonyl, or substituted or unsubstituted non-aromatic heterocyclesulfonyl; The compound according to the above [1] or

[10] , wherein m is 1 to 3, or a pharma- ceutically acceptable salt thereof.

[12] R 2b is substituted or unsubstituted alkyl, or a pharma- ceutically acceptable salt thereof.

[13] R 4a is a group shown below, or a pharma- ceutically acceptable salt thereof. [ka] (In the formula, L 3, and R 7 is equivalent to [1] above).

[14] L 3 is substituted or unsubstituted alkylene, or a pharma- ceutically acceptable salt thereof.

[15] R 7 is halogen, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, or a group of the formula: -LS(=O)(=NR N )-R S1 The compound according to the above

[14] , or a pharma- ceutically acceptable salt thereof.

[16] L 3 is a single bond, or a pharma- ceutically acceptable salt thereof.

[17] R 7 is a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted non-aromatic heterocyclic group, or a pharma- ceutically acceptable salt thereof.

[18] R 4b is a substituted or unsubstituted alkyl, a substituted or unsubstituted aromatic carbocyclic group, or a substituted or unsubstituted aromatic heterocyclic group, or a pharma- ceutically acceptable salt thereof.

[19] R 3a and R 3b is hydrogen, or a pharma- ceutically acceptable salt thereof.

[20] The compound according to the above [1], which is selected from the group consisting of compounds I-6, I-13, I-14, I-20, I-33, I-46, I-58, I-61, I-66, I-79, I-126, I-130, I-133, I-137 and I-142, or a pharma- ceutical acceptable salt thereof. [20-1] The compound according to the above [1], which is selected from the group consisting of compounds I-123, I-124, I-136, I-139, I-141, I-143, I-145 and I-147, or a pharma- ceutically acceptable salt thereof. [20-2] The compound according to the above [1], which is selected from the group consisting of compounds I-151 and I-153, or a pharma- ceutically acceptable salt thereof. [twenty one] A pharmaceutical composition comprising the compound according to any one of the above [1] to

[20] or [20-1] to [20-2] or a pharma- ceutically acceptable salt thereof. [twenty two] The pharmaceutical composition according to the above

[21] , which has an MGAT2 inhibitory effect. [twenty three] The pharmaceutical composition according to the above

[21] or

[22] , which is used for treating or preventing a disease in which MGAT2 is involved. [twenty four] The pharmaceutical composition according to

[23] above, which is used for the treatment or prevention of obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, hyperfatty acidemia, diabetes or arteriosclerosis.

[25] A method for treating or preventing a disease involving MGAT2, which comprises administering a compound according to any one of the above [1] to

[20] or [20-1] to [20-2], or a pharma- ceutically acceptable salt thereof.

[26] The compound according to any one of the above [1] to

[20] or [20-1] to [20-2], or a pharma- ceutically acceptable salt thereof, for treating or preventing a disease involving MGAT2.

[27] Use of the compound according to any one of the above [1] to

[20] or [20-1] to [20-2], or a pharma- ceutically acceptable salt thereof, for the treatment or prevention of a disease involving MGAT2.

[0008] [1'] Formula (I): [ka] (In the formula, R 1is hydrogen; R 2a and R 2b together with the adjacent carbon atom to form ring B, Ring B is of the formula: [ka] (In the formula, R 6 are each independently a halogen or a substituted or unsubstituted alkyloxy; n is 1 or 2; R 3a is hydrogen; R 3b is hydrogen; R 4a is the expression: [ka] (In the formula, L 3 is a single bond or a substituted or unsubstituted alkylene; R 7 is a halogen, a substituted or unsubstituted sulfamoyl, a substituted or unsubstituted alkyloxy, a substituted or unsubstituted alkylsulfonyl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted nonaromatic heterocyclic group, or a group of the formula: -S(=O)(=NR N )-R S1 and R N is hydrogen, R S1 is substituted or unsubstituted alkyl; R 4b is a substituted or unsubstituted alkyl, a substituted or unsubstituted aromatic carbocyclic group, or a substituted or unsubstituted aromatic heterocyclic group), or a pharma- ceutically acceptable salt thereof. [2'] The compound according to the above [1'], wherein ring B is represented by any one of the following formulas, or a pharma- ceutically acceptable salt thereof. formula: [ka] (In the formula, R 6 each independently is a substituted or unsubstituted alkyloxy. [3'] The compound according to the above [1'], wherein ring B is represented by any one of the following formulas, or a pharma- ceutically acceptable salt thereof. formula: [ka] (In the formula, R 6 are each independently a halogen or a substituted or unsubstituted alkyloxy. [4'] L 3 is substituted or unsubstituted alkylene, or a pharma- ceutically acceptable salt thereof. [5'] R 7 is a halogen, a substituted or unsubstituted sulfamoyl, a substituted or unsubstituted alkyloxy, a substituted or unsubstituted alkylsulfonyl, or a group of the formula: -S(=O)(=NR N )-R S1 The compound according to the above [4'], or a pharma- ceutically acceptable salt thereof. [6'] L 3 is a single bond, or a pharma- ceutically acceptable salt thereof. [7'] R 7 is a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted non-aromatic heterocyclic group, or a pharma- ceutically acceptable salt thereof. [8'] The compound according to the above [1'], which is selected from the group consisting of compounds I-6, I-13, I-14, I-20, I-33, I-46, I-58, I-61, I-66, I-79, I-126, I-130, I-133, I-137 and I-142, or a pharma- ceutical acceptable salt thereof. [8'-1] The compound according to the above [1'], which is selected from the group consisting of compounds I-123, I-124, I-136, I-139, I-141, I-143, I-145 and I-147, or a pharma- ceutically acceptable salt thereof. [8'-2] The compound according to the above [1'], which is selected from the group consisting of compounds I-151 and I-153, or a pharma- ceutically acceptable salt thereof. [9'] A pharmaceutical composition comprising the compound according to any one of the above [1'] to [8'] or [8'-1] to [8'-2] or a pharma- ceutically acceptable salt thereof. [10'] The pharmaceutical composition according to the above [9'], which has an MGAT2 inhibitory effect. [11'] The pharmaceutical composition according to the above [9'] or [10'], which is used for treating or preventing a disease in which MGAT2 is involved. [12'] The pharmaceutical composition according to the above [11'], which is used for the treatment or prevention of obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, hyperfatty acidemia, diabetes or arteriosclerosis. [13'] A method for treating or preventing a disease involving MGAT2, comprising administering a compound according to any one of [1'] to [8'] or [8'-1] to [8'-2] above, or a pharma- ceutically acceptable salt thereof. [14'] The compound according to any one of the above [1'] to [8'] or [8'-1] to [8'-2], or a pharma- ceutically acceptable salt thereof, for treating or preventing a disease involving MGAT2. [15'] Use of the compound according to any one of the above [1'] to [8'] or [8'-1] to [8'-2], or a pharma- ceutically acceptable salt thereof, for the treatment or prevention of a disease involving MGAT2. Effect of the Invention

[0009] The compound according to the present invention has an MGAT2 inhibitory effect and is useful as a preventive and / or therapeutic agent for obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, hyperfatty acidemia, diabetes or arteriosclerosis. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] The meaning of each term used in this specification will be explained below. Unless otherwise specified, each term has the same meaning whether it is used alone or in combination with other terms. The term "consisting of" means having only the constituent elements. The term "comprising" is meant to be open ended and does not exclude unrecited elements.

[0011] The term "halogen" includes fluorine, chlorine, bromine and iodine atoms. In particular, fluorine and chlorine atoms are preferred.

[0012] The term "alkyl" includes straight-chain or branched hydrocarbon groups having 1 to 15 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms, and even more preferably 1 to 4 carbon atoms. Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl, and n-decyl. Preferred embodiments of "alkyl" include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, and n-pentyl. More preferred embodiments include methyl, ethyl, n-propyl, isopropyl, and tert-butyl.

[0013] The term "alkenyl" includes linear or branched hydrocarbon groups having one or more double bonds at any position and having 2 to 15 carbon atoms, preferably 2 to 10 carbon atoms, more preferably 2 to 6 carbon atoms, and even more preferably 2 to 4 carbon atoms. Examples include vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl, and pentadecenyl. Preferred embodiments of "alkenyl" include vinyl, allyl, propenyl, isopropenyl and butenyl.

[0014] The term "alkynyl" refers to a linear or branched hydrocarbon group having 2 to 10 carbon atoms, preferably 2 to 8 carbon atoms, more preferably 2 to 6 carbon atoms, and even more preferably 2 to 4 carbon atoms, which has one or more triple bonds at any position. It may further have a double bond at any position. Examples of the group include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, and decynyl. Preferred embodiments of "alkynyl" include ethynyl, propynyl, butynyl and pentynyl.

[0015] The term "alkylene" includes a straight-chain or branched divalent hydrocarbon group having 1 to 15 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms, and even more preferably 1 to 4 carbon atoms. Examples include methylene, ethylene, propylene, tetramethylene, pentamethylene, and hexamethylene.

[0016] The term "aromatic carbocyclic group" refers to a monocyclic or bicyclic or more aromatic hydrocarbon group, such as phenyl, naphthyl, anthryl, and phenanthryl. A preferred embodiment of the "aromatic carbocyclic group" is phenyl.

[0017] The term "non-aromatic carbocyclic group" refers to a monocyclic or bicyclic or more cyclic saturated or unsaturated non-aromatic hydrocarbon group. The term "non-aromatic carbocyclic group" having two or more rings also includes a monocyclic or bicyclic or more cyclic non-aromatic carbocyclic group to which the rings of the above-mentioned "aromatic carbocyclic group" are condensed. In addition, "non-aromatic carbocyclic group" also includes groups that form bridged or spiro rings, such as those described below. [ka] The monocyclic non-aromatic carbocyclic group preferably has 3 to 16 carbon atoms, more preferably 3 to 12 carbon atoms, and further preferably 4 to 8 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclohexadienyl, and the like. The non-aromatic carbocyclic group having two or more rings preferably has 8 to 20 carbon atoms, and more preferably has 8 to 16 carbon atoms. Examples include indanyl, indenyl, acenaphthyl, tetrahydronaphthyl, and fluorenyl.

[0018] The term "aromatic carbocycle" includes cyclic aromatic hydrocarbons having a single ring or two or more rings, such as a benzene ring, a naphthalene ring, an anthracene ring, and a phenanthrene ring. One embodiment of the "aromatic carbocyclic ring" is a benzene ring or a naphthalene ring. Another embodiment is a benzene ring. The term "non-aromatic carbocycle" includes monocyclic or bicyclic or more cyclic saturated or non-aromatic unsaturated hydrocarbons. The term "non-aromatic carbocycle" with bicyclic or more rings also includes a monocyclic or bicyclic or more non-aromatic carbocycle fused with the ring of the above-mentioned "aromatic carbocycle". In addition, "nonaromatic carbocycle" also includes rings that are bridged or form spirocycles as described below. [ka] The monocyclic non-aromatic carbocyclic ring preferably has 3 to 16 carbon atoms, more preferably 3 to 12 carbon atoms, and further preferably 3 to 8 carbon atoms. Examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclohexadiene, and the like. The non-aromatic carbon ring having two or more rings preferably has a carbon number of 8 to 20, more preferably a carbon number of 8 to 16. Examples thereof include indane, indene, acenaphthylene, tetrahydronaphthalene, and fluorene.

[0019] The term "aromatic heterocyclic group" refers to a monocyclic or bicyclic or more aromatic cyclic group having in the ring one or more identical or different heteroatoms selected from O, S, and N. A bicyclic or more aromatic heterocyclic group also includes a monocyclic or bicyclic or more aromatic heterocyclic group to which the ring in the above-mentioned "aromatic carbocyclic group" is condensed. The monocyclic aromatic heterocyclic group is preferably 5- to 8-membered, more preferably 5- or 6-membered, for example, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, thiadiazolyl, etc. The bicyclic aromatic heterocyclic group is preferably 8- to 10-membered, more preferably 9- or 10-membered. Examples thereof include indolyl, isoindolyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl, imidazothiazolyl, pyrazinopyridazinyl, oxazolopyridyl, and thiazolopyridyl. Examples of the aromatic heterocyclic group having three or more rings include carbazolyl, acridinyl, xanthenyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, dibenzofuryl, and the like.

[0020] The term "non-aromatic heterocyclic group" refers to a monocyclic or bicyclic or more cyclic non-aromatic cyclic group having in the ring one or more identical or different heteroatoms selected from O, S, and N. A bicyclic or more non-aromatic heterocyclic group includes a monocyclic or bicyclic or more non-aromatic heterocyclic group fused with each of the rings in the above-mentioned "aromatic carbocyclic group", "non-aromatic carbocyclic group", and / or "aromatic heterocyclic group", as well as a monocyclic or bicyclic or more non-aromatic carbocyclic group fused with a ring in the above-mentioned "aromatic heterocyclic group". In addition, "non-aromatic heterocyclic group" also includes groups that form bridged or spiro rings, such as: [ka] The monocyclic non-aromatic heterocyclic group is preferably a 3- to 8-membered group, and more preferably a 5- or 6-membered group. For example, dioxanyl, thiiranyl, oxiranyl, oxetanyl, oxathiolanyl, azetidinyl, thianyl, thiazolidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, dihydropyridyl, tetrahydropyridyl, tetrahydrofuryl, tetrahydropyranyl, dihydrothiazolyl, tetrahydrothiazolyl, tetrahydroisothiazolyl, dihydrooxazinyl, hexahydroazepinyl, tetrahydrodiazepinyl, tetrahydropyridazinyl, hexahydropyrimidinyl, dioxolanyl, dioxazinyl, aziridinyl, dioxolinyl, oxepanyl, thiolanyl, thiinyl, thiazinyl, and the like. The non-aromatic heterocyclic group having two or more rings is preferably 8 to 20-membered, and more preferably 8 to 10-membered, and examples thereof include indolinyl, isoindolinyl, chromanyl, and isochromanyl.

[0021] The term "aromatic heterocycle" includes a monocyclic or two or more aromatic rings having one or more identical or different heteroatoms selected from O, S and N in the ring. The "aromatic heterocycle" having two or more rings also includes a monocyclic or two or more rings of an aromatic heterocycle condensed with the ring in the above-mentioned "aromatic carbocycle". The monocyclic aromatic heterocycle is preferably 5- to 8-membered, more preferably 5- or 6-membered, and examples thereof include pyrrole, imidazole, pyrazole, pyridine, pyridazine, pyrimidine, pyrazine, triazole, triazine, tetrazole, furan, thiophene, isoxazole, oxazole, oxadiazole, isothiazole, thiazole, and thiadiazole. The bicyclic aromatic heterocycle is preferably 8- to 10-membered, more preferably 9- or 10-membered. Examples thereof include indole, isoindole, indazole, indolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, naphthyridine, quinoxaline, purine, pteridine, benzimidazole, benzisoxazole, benzoxazole, benzoxadiazole, benzisothiazole, benzothiazole, benzothiadiazole, benzofuran, isobenzofuran, benzothiophene, benzotriazole, imidazopyridine, triazolopyridine, imidazothiazole, pyrazinopyridazine, oxazolopyridine, and thiazolopyridine. The aromatic heterocycle having three or more rings is preferably 11 to 26-membered, more preferably 13 or 14-membered, for example, carbazole, acridine, xanthene, phenothiazine, phenoxathiin, phenoxazine, dibenzofuran, etc. The term "non-aromatic heterocycle" includes a monocyclic or bicyclic or more cyclic non-aromatic ring having one or more identical or different heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms in the ring. The term "non-aromatic heterocycle" having two or more rings also includes a monocycle or two or more non-aromatic heterocycles to which each of the above-mentioned "aromatic carbocycles", "non-aromatic carbocycles", and / or "aromatic heterocycles" is condensed. In addition, "non-aromatic heterocycle" also includes rings that are bridged or form spirocycles, as described below. [ka] The monocyclic non-aromatic heterocycle is preferably 3- to 8-membered, more preferably 5- or 6-membered. Examples thereof include dioxane, thiirane, oxirane, oxetane, oxathiolane, azetidine, thiane, thiazolidine, pyrrolidine, pyrroline, imidazolidine, imidazoline, pyrazolidine, pyrazoline, piperidine, piperazine, morpholine, thiomorpholine, dihydropyridine, tetrahydropyridine, tetrahydrofuran, tetrahydropyran, dihydrothiazole, tetrahydrothiazole, tetrahydroisothiazole, dihydrooxazine, hexahydroazepine, tetrahydrodiazepine, tetrahydropyridazine, hexahydropyrimidine, dioxolane, dioxazine, aziridine, dioxole, oxepane, thiolane, thiine, and thiazine. The non-aromatic heterocycle having two or more rings is preferably 8 to 20-membered, and more preferably 8 to 10-membered. Examples thereof include indoline, isoindoline, chroman, and isochroman.

[0022] Substituents for "substituted carbamoyl", "substituted thiocarbamoyl", "substituted amidino", "substituted amino", "substituted ureido", "substituted guanidino", "substituted sulfamoyl", "substituted alkyl", "substituted alkenyl", "substituted alkynyl", "substituted alkylene", "substituted alkyloxy", "substituted alkenyloxy", "substituted alkylcarbonyloxy", "substituted alkenylcarbonyloxy", "substituted alkylcarbonyl", "substituted alkenylcarbonyl", "substituted alkyloxycarbonyl", "substituted alkenyloxycarbonyl", "substituted alkylsulfanyl", "substituted alkenylsulfanyl", "substituted alkylsulfinyl", "substituted alkenylsulfinyl", "substituted alkylsulfonyl", and "substituted alkenylsulfonyl" include the following substituents. Carbon atoms or nitrogen atoms at any position may be bonded to one or more groups selected from the following substituents. Substituents: halogen, hydroxy, cyano, formyl, formyloxy, thioformyl, carboxy, thiocarboxy, dithiocarboxy, carbamoyl, thiocarbamoyl, amidino, amino, hydroxyamino, hydroxyimino, azido, hydrazino, ureido, guanidino, pentafluorothio, thiol, sulfino, sulfo, sulfamoyl, trialkylsilyl, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, alkyloxy, alkenyloxy, alkynyloxy, haloalkyloxy, haloal. alkyloxyalkyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylsulfanyl, alkenylsulfanyl, alkynylsulfanyl, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, monoalkylaminosulfonyl, monoalkenyl a aminosulfonyl, monoalkynylaminosulfonyl, dialkylaminosulfonyl, dialkenylaminosulfonyl, dialkynylaminosulfonyl, monoalkylamino, monoalkenylamino, monoalkynylamino, dialkylamino, dialkenylamino, dialkynylamino, monoalkylcarbonylamino, monoalkenylcarbonylamino, monoalkynylcarbonylamino, dialkylcarbonylamino, dialkenylcarbonylamino, dialkynylcarbonylamino, monoalkyloxycarbonylamino, monoalkenyloxycarbonylamino carboxyamino, monoalkynyloxycarbonylamino, dialkyloxycarbonylamino, dialkenyloxycarbonylamino, dialkynyloxycarbonylamino, monoalkylsulfonylamino, monoalkenylsulfonylamino, monoalkynylsulfonylamino, dialkylsulfonylamino, dialkenylsulfonylamino, dialkynylsulfonylamino, monoalkylcarbamoyl, monoalkenylcarbamoyl, monoalkynylcarbamoyl, dialkylcarbamoyl, dialkenylcarbamoyl, dialkynylcarbamoyl,Monoalkyloxycarbamoyl, monoalkenyloxycarbamoyl, monoalkynyloxycarbamoyl, dialkyloxycarbamoyl, dialkenyloxycarbamoyl, dialkynyloxycarbamoyl, monoalkylcarbonylcarbamoyl, monoalkenylcarbonylcarbamoyl, monoalkynylcarbonylcarbamoyl, monoalkyloxycarbonylcarbamoyl, monoalkenyloxycarbonylcarbamoyl, monoalkynyloxycarbonylcarbamoyl, monoalkylsulfonylcarbamoyl, monoalkenylsulf Nylcarbamoyl, monoalkynylsulfonylcarbamoyl, monoalkylsulfamoyl, monoalkenylsulfamoyl, monoalkynylsulfamoyl, dialkylsulfamoyl, dialkenylsulfamoyl, dialkynylsulfamoyl, monoalkyloxysulfamoyl, monoalkenyloxysulfamoyl, monoalkynyloxysulfamoyl, dialkyloxysulfamoyl, dialkenyloxysulfamoyl, dialkynyoxysulfamoyl, monoalkylcarbonylsulfamoyl, monoalkenylcarbonyl monosulfamoyl, monoalkynylcarbonylsulfamoyl, monoalkyloxycarbonylsulfamoyl, monoalkenyloxycarbonylsulfamoyl, monoalkynyloxycarbonylsulfamoyl, monoalkylsulfonylsulfamoyl, monoalkenylsulfonylsulfamoyl, monoalkynylsulfonylsulfamoyl, aromatic carbocyclic groups optionally substituted with substituent group A, non-aromatic carbocyclic groups optionally substituted with substituent group A, aromatic heterocyclic groups optionally substituted with substituent group A, non-aromatic heterocyclic groups optionally substituted with substituent group A a cyclic group, an aromatic carbocyclic oxy which may be substituted with substituent group A, a non-aromatic carbocyclic oxy which may be substituted with substituent group A, an aromatic heterocyclic oxy which may be substituted with substituent group A, a non-aromatic heterocyclic oxy which may be substituted with substituent group A, an aromatic carbocyclic carbonyloxy which may be substituted with substituent group A, a non-aromatic carbocyclic carbonyloxy which may be substituted with substituent group A, an aromatic heterocyclic carbonyloxy which may be substituted with substituent group A, a non-aromatic heterocyclic carbonyloxy which may be substituted with substituent group A, an aromatic carbocyclic carbonyl which may be substituted with substituent group A,Non-aromatic carbocyclic carbonyl optionally substituted with substituent group A, aromatic heterocyclic carbonyl optionally substituted with substituent group A, non-aromatic heterocyclic carbonyl optionally substituted with substituent group A, aromatic carbocyclic oxycarbonyl optionally substituted with substituent group A, non-aromatic carbocyclic oxycarbonyl optionally substituted with substituent group A, aromatic heterocyclic oxycarbonyl optionally substituted with substituent group A, non-aromatic heterocyclic oxycarbonyl optionally substituted with substituent group A, aromatic carbocyclic sulfanyl optionally substituted with substituent group A, non-aromatic carbon optionally substituted with substituent group A ring sulfanyl, aromatic heterocyclic sulfanyl optionally substituted with substituent group A, non-aromatic heterocyclic sulfanyl optionally substituted with substituent group A, aromatic carbocyclic sulfinyl optionally substituted with substituent group A, non-aromatic carbocyclic sulfinyl optionally substituted with substituent group A, aromatic heterocyclic sulfinyl optionally substituted with substituent group A, non-aromatic heterocyclic sulfinyl optionally substituted with substituent group A, aromatic carbocyclic sulfonyl optionally substituted with substituent group A, non-aromatic carbocyclic sulfonyl optionally substituted with substituent group A, aromatic heterocyclic sulfonyl, non-aromatic heterocyclic sulfonyl optionally substituted with substituent group A, aromatic carbocyclic alkyl optionally substituted with substituent group A, non-aromatic carbocyclic alkyl optionally substituted with substituent group A, aromatic heterocyclic alkyl optionally substituted with substituent group A, non-aromatic heterocyclic alkyl optionally substituted with substituent group A, aromatic carbocyclic alkyloxy optionally substituted with substituent group A, non-aromatic carbocyclic alkyloxy optionally substituted with substituent group A, aromatic heterocyclic alkyloxy optionally substituted with substituent group A, non-aromatic heterocyclic alkyloxy optionally substituted with substituent group A, aromatic carbocyclic alkylcarbonyl optionally substituted with substituent group A, non-aromatic carbocyclic alkylcarbonyl optionally substituted with substituent group A, aromatic heterocyclic alkylcarbonyl optionally substituted with substituent group A, non-aromatic heterocyclic alkylcarbonyl optionally substituted with substituent group A, aromatic carbocyclic alkyloxycarbonyl optionally substituted with substituent group A, non-aromatic carbocyclic alkyloxycarbonyl optionally substituted with substituent group A,Aromatic carbocyclic alkylsulfanyl optionally substituted with substituent group A, non-aromatic carbocyclic alkylsulfanyl optionally substituted with substituent group A, aromatic heterocyclic alkylsulfanyl optionally substituted with substituent group A, non-aromatic heterocyclic alkylsulfanyl optionally substituted with substituent group A, aromatic carbocyclic alkylsulfinyl optionally substituted with substituent group A, non-aromatic carbocyclic alkylsulfinyl optionally substituted with substituent group A, aromatic heterocyclic alkylsulfinyl optionally substituted with substituent group A, non-aromatic heterocyclic alkylsulfinyl optionally substituted with substituent group A, aromatic carbocyclic alkylsulfonyl optionally substituted with substituent group A, non-aromatic carbocyclic alkylsulfonyl optionally substituted with substituent group A, aromatic heterocyclic alkylsulfonyl optionally substituted with substituent group A, non-aromatic heterocyclic alkylsulfonyl optionally substituted with substituent group A, aromatic carbocyclic alkylamino optionally substituted with substituent group A, non-aromatic carbocyclic alkylamino optionally substituted with substituent group A, aromatic heterocyclic alkylamino optionally substituted with substituent group A, non-aromatic heterocyclic alkylamino optionally substituted with substituent group A, aromatic carbocyclic alkylcarbonylamino which may be substituted with substituent group A, non-aromatic carbocyclic alkylcarbonylamino which may be substituted with substituent group A, aromatic heterocyclic alkylcarbonylamino which may be substituted with substituent group A, non-aromatic heterocyclic alkylcarbonylamino which may be substituted with substituent group A, aromatic carbocyclic alkyloxycarbonylamino which may be substituted with substituent group A, non-aromatic carbocyclic alkyloxycarbonylamino which may be substituted with substituent group A, aromatic heterocyclic alkyloxycarbonylamino which may be substituted with substituent group A, non-aromatic heterocyclic alkyloxycarbonylamino which may be substituted with substituent group A, aromatic carbocyclic alkylsulfonylamino which may be substituted with substituent group A, non-aromatic carbocyclic alkylsulfonylamino which may be substituted with substituent group A, aromatic heterocyclic alkylsulfonylamino which may be substituted with substituent group A, non-aromatic heterocyclic alkylsulfonylamino which may be substituted with substituent group A, aromatic carbocyclic oxyalkylamino which may be substituted with substituent group A, non-aromatic carbocyclic oxyalkylamino which may be substituted with substituent group A, aromatic heterocyclic oxyalkylamino which may be substituted with substituent group A,and non-aromatic heterocyclic oxyalkylamino optionally substituted with the substituent group A. The phrase "may be substituted with substituent group A" means that a carbon atom, nitrogen atom or sulfur atom at any position may be bonded to one or more groups selected from substituent group A. Substituent group A: oxo, halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkyloxy, haloalkyloxy, alkyloxycarbonylalkyl, monoalkylamino, dialkylamino, aromatic carbocyclic group, aromatic heterocyclic group, and aromatic carbocyclicoxy. The same applies below to "may be substituted with substituent group B." Substituent group B: halogen, alkyl, and haloalkyl.

[0023] "substituted non-aromatic carbocycle", "substituted non-aromatic heterocycle", "substituted aromatic carbocyclic group", "substituted non-aromatic carbocyclic group", "substituted aromatic heterocyclic group", "substituted non-aromatic heterocyclic group", "substituted aromatic carbocycleoxy", "substituted non-aromatic carbocycleoxy", "substituted aromatic heterocycleoxy", "substituted non-aromatic heterocycleoxy", "substituted aromatic carbocyclecarbonyloxy", "substituted non-aromatic carbocyclecarbonyloxy", "substituted aromatic heterocyclecarbonyloxy", "substituted non-aromatic heterocyclecarbonyloxy", "substituted aromatic carbocyclecarbonyl", "substituted non-aromatic carbocyclecarbonyl", "substituted aromatic heterocyclecarbonyl", "substituted non-aromatic heterocyclecarbonyl", "substituted aromatic carbocycleoxycarbonyl", "substituted non-aromatic carbocycleoxycarbo "Nyl", "substituted aromatic heterocyclic oxycarbonyl", "substituted non-aromatic heterocyclic oxycarbonyl", "substituted aromatic carbocyclic sulfanyl", "substituted non-aromatic carbocyclic sulfanyl", "substituted aromatic heterocyclic sulfanyl", "substituted non-aromatic heterocyclic sulfanyl", "substituted aromatic carbocyclic sulfinyl", "substituted non-aromatic carbocyclic sulfinyl", "substituted aromatic heterocyclic sulfinyl", "substituted non-aromatic heterocyclic sulfinyl", "substituted aromatic carbocyclic sulfonyl", "substituted non-aromatic carbocyclic sulfonyl", "substituted aromatic heterocyclic sulfonyl", and "substituted non-aromatic heterocyclic sulfonyl" are examples of the substituents on the ring of "aromatic carbocyclic ring", "non-aromatic carbocyclic ring", "aromatic heterocyclic ring" and "non-aromatic heterocyclic ring". The following substituents can be included as the substituents on the ring. An atom at any position on the ring may be bonded to one or more groups selected from the following substituents. Substituents: oxo, halogen, hydroxy, cyano, formyl, formyloxy, thioformyl, carboxy, thiocarboxy, dithiocarboxy, carbamoyl, thiocarbamoyl, amidino, amino, hydroxyamino, imino, hydroxyimino, azido, hydrazino, ureido, guanidino, pentafluorothio, thiol, sulfino, sulfo, sulfamoyl, trialkylsilyl, alkyl, alkenyl, alkynyl, haloalkyl, alkyloxy, alkenyloxy, alkynyloxy, haloalkyloxy, haloalken ...alkyloxy, haloalkenyloxy, haloalkyloxy, haloalkyloxy, haloalkenyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkenyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkenyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkenyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkenyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkenyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, haloalkyloxy, ha alkenyloxy, alkyloxyalkyloxy, haloalkyloxyalkyloxy, hydroxyalkyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylsulfanyl, alkenylsulfanyl, alkynylsulfanyl, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, alkylsulfonyl, alkenyl Nilsulfonyl, alkynylsulfonyl, monoalkylaminosulfonyl, monoalkenylaminosulfonyl, monoalkynylaminosulfonyl, dialkylaminosulfonyl, dialkenylaminosulfonyl, dialkynylaminosulfonyl, monoalkylamino, monoalkenylamino, monoalkynylamino, monohaloalkylamino, dialkylamino, dialkenylamino, dialkynylamino, monoalkylcarbonylamino, monoalkenylcarbonylamino, monoalkynylcarbonylamino, monohaloalkylcarbonylamino, di alkylcarbonylamino, dialkenylcarbonylamino, dialkynylcarbonylamino, monoalkyloxycarbonylamino, monoalkenyloxycarbonylamino, monoalkynyloxycarbonylamino, dialkyloxycarbonylamino, dialkenyloxycarbonylamino, dialkynyloxycarbonylamino, monoalkylsulfonylamino, monoalkenylsulfonylamino, monoalkynylsulfonylamino, dialkylsulfonylamino, dialkenylsulfonylamino, dialkynylsulfonylamino, alkylimino,Alkenylimino, alkynylimino, alkyloxyimino, alkenyloxyimino, alkynyloxyimino, monoalkylcarbamoyl, monoalkenylcarbamoyl, monoalkynylcarbamoyl, dialkylcarbamoyl, dialkenylcarbamoyl, dialkynylcarbamoyl, monoalkyloxycarbamoyl, monoalkenyloxycarbamoyl, monoalkynyloxycarbamoyl, dialkyloxycarbamoyl, dialkenyloxycarbamoyl, dialkynyloxycarbamoyl, monoalkylcarbonylcarbamoyl, monoa alkenylcarbonylcarbamoyl, monoalkynylcarbonylcarbamoyl, monoalkyloxycarbonylcarbamoyl, monoalkenyloxycarbonylcarbamoyl, monoalkynyloxycarbonylcarbamoyl, monoalkylsulfonylcarbamoyl, monoalkenylsulfonylcarbamoyl, monoalkynylsulfonylcarbamoyl, monoalkylsulfamoyl, monoalkenylsulfamoyl, monoalkynylsulfamoyl, dialkylsulfamoyl, dialkenylsulfamoyl, dialkynylsulfamoyl, monoalkyloxy Sulfamoyl, monoalkenyloxysulfamoyl, monoalkynyloxysulfamoyl, dialkyloxysulfamoyl, dialkenyloxysulfamoyl, dialkynyloxysulfamoyl, monoalkylcarbonylsulfamoyl, monoalkenylcarbonylsulfamoyl, monoalkynylcarbonylsulfamoyl, monoalkyloxycarbonylsulfamoyl, monoalkenyloxycarbonylsulfamoyl, monoalkynyloxycarbonylsulfamoyl, monoalkylsulfonylsulfamoyl, monoalkenylsulf nylsulfamoyl, monoalkynylsulfonylsulfamoyl, an aromatic carbocyclic group optionally substituted with substituent group A, a non-aromatic carbocyclic group optionally substituted with substituent group A, an aromatic heterocyclic group optionally substituted with substituent group A, a non-aromatic heterocyclic group optionally substituted with substituent group A, an aromatic carbocyclic oxy optionally substituted with substituent group A, a non-aromatic carbocyclic oxy optionally substituted with substituent group A, an aromatic heterocyclic oxy optionally substituted with substituent group A, a non-aromatic heterocyclic oxy optionally substituted with substituent group A, an aromatic carbocyclic carbonyloxy optionally substituted with substituent group A,Non-aromatic carbocyclic carbonyloxy optionally substituted with substituent group A, aromatic heterocyclic carbonyloxy optionally substituted with substituent group A, non-aromatic heterocyclic carbonyloxy optionally substituted with substituent group A, aromatic carbocyclic carbonyl optionally substituted with substituent group A, non-aromatic carbocyclic carbonyl optionally substituted with substituent group A, aromatic heterocyclic carbonyl optionally substituted with substituent group A, non-aromatic heterocyclic carbonyl optionally substituted with substituent group A, aromatic carbocyclic oxycarbonyl optionally substituted with substituent group A, non-aromatic carbocyclic optionally substituted with substituent group A Oxycarbonyl, aromatic heterocyclic oxycarbonyl optionally substituted with substituent group A, non-aromatic heterocyclic oxycarbonyl optionally substituted with substituent group A, aromatic carbocyclic sulfanyl optionally substituted with substituent group A, non-aromatic carbocyclic sulfanyl optionally substituted with substituent group A, aromatic heterocyclic sulfanyl optionally substituted with substituent group A, non-aromatic heterocyclic sulfanyl optionally substituted with substituent group A, aromatic carbocyclic sulfinyl optionally substituted with substituent group A, non-aromatic carbocyclic sulfinyl optionally substituted with substituent group A, aromatic heterocyclic sulfinyl optionally substituted with substituent group A, non-aromatic heterocyclic sulfinyl optionally substituted with substituent group A, aromatic carbocyclic sulfonyl optionally substituted with substituent group A, non-aromatic carbocyclic sulfonyl optionally substituted with substituent group A, aromatic heterocyclic sulfonyl optionally substituted with substituent group A, non-aromatic heterocyclic sulfonyl optionally substituted with substituent group A, aromatic carbocyclic amino optionally substituted with substituent group A, non-aromatic carbocyclic amino optionally substituted with substituent group A, aromatic heterocyclic amino optionally substituted with substituent group A, non-aromatic heterocyclic amino optionally substituted with substituent group A, aromatic carbocyclic alkyl optionally substituted with substituent group A, non-aromatic carbocyclic alkyl optionally substituted with substituent group A, aromatic heterocyclic alkyl optionally substituted with substituent group A, non-aromatic heterocyclic alkyl optionally substituted with substituent group A, aromatic carbocyclic alkyloxy optionally substituted with substituent group A, non-aromatic carbocyclic alkyloxy optionally substituted with substituent group A, aromatic heterocyclic alkyloxy optionally substituted with substituent group A, non-aromatic heterocyclic alkyloxy optionally substituted with substituent group A, aromatic carbocyclic alkylcarbonyl optionally substituted with substituent group A,Non-aromatic carbocyclic alkylcarbonyl optionally substituted with substituent group A, aromatic heterocyclic alkylcarbonyl optionally substituted with substituent group A, non-aromatic heterocyclic alkylcarbonyl optionally substituted with substituent group A, aromatic carbocyclic alkyloxycarbonyl optionally substituted with substituent group A, non-aromatic carbocyclic alkyloxycarbonyl optionally substituted with substituent group A, aromatic heterocyclic alkyloxycarbonyl optionally substituted with substituent group A, non-aromatic heterocyclic alkyloxycarbonyl optionally substituted with substituent group A, aromatic carbocyclic alkylsulfanyl optionally substituted with substituent group A, non-aromatic carbocyclic alkylsulfanyl optionally substituted with substituent group A, aromatic heterocyclic alkylsulfanyl optionally substituted with substituent group A, non-aromatic heterocyclic alkylsulfanyl optionally substituted with substituent group A, aromatic carbocyclic alkylsulfinyl optionally substituted with substituent group A, non-aromatic carbocyclic alkylsulfinyl optionally substituted with substituent group A, aromatic heterocyclic alkylsulfinyl optionally substituted with substituent group A, non-aromatic heterocyclic alkylsulfinyl optionally substituted with substituent group A, aromatic carbocyclic alkylsulfinyl optionally substituted with substituent group A, ring alkylsulfonyl, non-aromatic carbocyclic alkylsulfonyl optionally substituted with substituent group A, aromatic heterocyclic alkylsulfonyl optionally substituted with substituent group A, non-aromatic heterocyclic alkylsulfonyl optionally substituted with substituent group A, aromatic carbocyclic alkylamino optionally substituted with substituent group A, non-aromatic carbocyclic alkylamino optionally substituted with substituent group A, aromatic heterocyclic alkylamino optionally substituted with substituent group A, non-aromatic heterocyclic alkylamino optionally substituted with substituent group A, aromatic carbocyclic alkylcarbonylamino optionally substituted with substituent group A, non-aromatic carbocyclic alkylcarbonylamino optionally substituted with substituent group A, aromatic heterocyclic alkylcarbonylamino optionally substituted with substituent group A, non-aromatic heterocyclic alkylcarbonylamino optionally substituted with substituent group A, aromatic carbocyclic alkyloxycarbonylamino optionally substituted with substituent group A, non-aromatic carbocyclic alkyloxycarbonylamino optionally substituted with substituent group A, aromatic heterocyclic alkyloxycarbonylamino optionally substituted with substituent group A, non-aromatic heterocyclic alkyloxycarbonylamino optionally substituted with substituent group A,Aromatic carbocyclic alkylsulfonylamino which may be substituted with substituent group A, non-aromatic carbocyclic alkylsulfonylamino which may be substituted with substituent group A, aromatic heterocyclic alkylsulfonylamino which may be substituted with substituent group A, non-aromatic heterocyclic alkylsulfonylamino which may be substituted with substituent group A, aromatic carbocyclic oxyalkylamino which may be substituted with substituent group A, non-aromatic carbocyclic oxyalkylamino which may be substituted with substituent group A, aromatic heterocyclic oxyalkylamino which may be substituted with substituent group A, and non-aromatic heterocyclic oxyalkylamino which may be substituted with substituent group A.

[0024] In the compound represented by formula (I), the embodiments and preferred embodiments of each substituent are shown below. Compounds having possible combinations of the embodiments of each substituent shown below are preferred.

[0025] R 1 Examples of the aryl group include hydrogen, hydroxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic carbocyclic groups, substituted or unsubstituted non-aromatic carbocyclic groups, substituted or unsubstituted aromatic heterocyclic groups, substituted or unsubstituted non-aromatic heterocyclic groups, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted Examples of the heterocyclic ring include substituted or unsubstituted aromatic carbocycle carbonyl, substituted or unsubstituted non-aromatic heterocycle carbonyl, substituted or unsubstituted aromatic carbocycle oxycarbonyl, substituted or unsubstituted non-aromatic carbocycle oxycarbonyl, substituted or unsubstituted aromatic heterocycle oxycarbonyl, substituted or unsubstituted non-aromatic heterocycle oxycarbonyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, and substituted or unsubstituted non-aromatic heterocycle sulfonyl. R 1 Preferred embodiments of include hydrogen and hydroxy. R 1A more preferred embodiment of the formula is hydrogen. R 1 When is substituted, examples of the substituent include halogen, hydroxy, amino, alkyl, monoalkylamino, dialkylamino, aromatic carbocyclic groups, non-aromatic carbocyclic groups, aromatic heterocyclic groups, or non-aromatic heterocyclic groups.

[0026] R 2a and R 2b is a preferred embodiment in which it forms ring B together with the adjacent carbon atom. R 2a and R 2b As another embodiment of the present invention, the following embodiment is also preferred: R 2a is the expression: [ka] and R 2b is hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted alkylsulfonyl. R 2b In a more preferred embodiment, it is hydrogen or substituted or unsubstituted alkyl. R 2b Particularly preferred embodiments of the group include substituted or unsubstituted alkyl, and in particular, alkyl and haloalkyl are preferred. In addition, R 2b When is substituted, examples of the substituents include halogen.

[0027] Ring B includes a substituted or unsubstituted non-aromatic carbocyclic ring, or a substituted or unsubstituted non-aromatic heterocyclic ring. A preferred embodiment of ring B is a ring having the formula: [ka] Examples include: A further preferred embodiment of ring B is a ring represented by the formula: [ka] Examples include: Particularly preferred embodiments of ring B include the formula: [ka] Examples include: Another preferred embodiment of ring B is a ring having the formula: [ka] More preferably, the formula: [ka] Examples include: Another preferred embodiment of ring B is a ring having the formula: [ka] More preferably, the formula: [ka] Of these, the formula: [ka] Examples include: Another preferred embodiment of ring B is a ring having the formula: [ka] More preferably, the formula: [ka] Examples include: Another preferred embodiment of ring B is a ring having the formula: [ka] More preferably, the formula: [ka] Examples include:

[0028] Yet another embodiment of ring B is a ring having the formula: [ka] Examples include:

[0029] Ring D can be an aromatic carbocycle, a non-aromatic carbocycle, an aromatic heterocycle, or a non-aromatic heterocycle. A preferred embodiment of ring D is an aromatic carbocyclic ring.

[0030] B 1 As for CR 11a R 11b , N.R. 11c , O, or S. B 1 A preferred embodiment of the method is CR 11a R 11b Examples include: B 1 A more preferred embodiment of the formula (I) is C.

[0031] B 2 As for CR 12a R 12b , N.R. 12c , O, or S. B 2 A preferred embodiment of the method is CR 12a R 12b Examples include: B 2 A more preferred embodiment of the formula (I) is C.

[0032] B 3 As for CR13a R 13b , N.R. 13c , O, or S. B 3 A preferred embodiment of the method is CR 13a R 13b , or O. B 3 Preferred specific embodiments of include, for example, CH2 or O.

[0033] B 4 As for CR 14a R 14b , N.R. 14c , O, or S. B 4 A preferred embodiment of the method is CR 14a R 14b Examples include: B 4 Preferred specific embodiments of the group include CH2 and CF2.

[0034] B 5 As for CR 15a R 15b , N.R. 15c , O, or S. B 5 A preferred embodiment of the method is CR 15a R 15b Examples include: B 5 A preferred specific embodiment of the above is CH2.

[0035] However, -B 1 -B 2 -B 3 -B 4 -or- B 1 -B 2 -B 3 -B 4 -B 5 However, there is no case where three or more consecutive atoms of any one of N, O, and S are bonded, such as -OOOO- or -SSSS-.

[0036] R 11a , R12a , R 13a , R 14a , and R 15aare each independently hydrogen, halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcapryloxy, substituted or unsubstituted alkylcarbonyl ... carboxyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or an unsubstituted aromatic carbocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted aromatic carbocycle-oxy, a substituted or unsubstituted non-aromatic carbocycle-oxy, a substituted or unsubstituted aromatic heterocycle-oxy, a substituted or unsubstituted non-aromatic heterocycle-oxy, a substituted or unsubstituted aromatic carbocycle-carbonyloxy, a substituted or unsubstituted non-aromatic carbocycle-carbonyloxy, a substituted or unsubstituted aromatic heterocycle-carbonyloxy, a substituted or unsubstituted non-aromatic heterocycle heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl,Substituted or unsubstituted aromatic heterocycle sulfanyl, substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -LN=S(=O)(-R, S1 )-R S2 , formula:-LS(=O)(=NR N )-R S1 , formula:-N=S(=NR N )(-R S1 )-R S2 , or the formula: -S(=NR N )2-R S1 Examples of the groups include those represented by the following formula: Here, the formula: -LN=S(=O)(-R S1 )-R S2 , formula:-LS(=O)(=NR N )-R S1 , formula:-N=S(=NR N )(-R S1 )-R S2 , Formula: -S(=NR N )2-R S1 The groups represented by the following formula (1) each have the following chemical structure: [ka] R 11a , R 12a , R 13a , R 14a , and R 15a Preferred embodiments of each independently include hydrogen, halogen, or substituted or unsubstituted alkyl. R 11a , R 12a , R 13a , R 14a , and R 15a More preferred embodiments of the group include hydrogen and halogen. R 11a , R 12a , R 13a , R 14a , and R 15a When is substituted, the substituents are each independently halogen, hydroxy, amino, alkyl, monoalkylamino, dialkylamino, an aromatic carbocyclic group, a non-aromatic carbocyclic group, an aromatic heterocyclic group, or a non-aromatic heterocyclic group.

[0037] R 11b , R 12b , R 13b , R 14b , and R 15bare each independently hydrogen, halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcapryloxy, substituted or unsubstituted alkylcarbonyl ... carboxyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or an unsubstituted aromatic carbocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted aromatic carbocycle-oxy, a substituted or unsubstituted non-aromatic carbocycle-oxy, a substituted or unsubstituted aromatic heterocycle-oxy, a substituted or unsubstituted non-aromatic heterocycle-oxy, a substituted or unsubstituted aromatic carbocycle-carbonyloxy, a substituted or unsubstituted non-aromatic carbocycle-carbonyloxy, a substituted or unsubstituted aromatic heterocycle-carbonyloxy, a substituted or unsubstituted non-aromatic heterocycle heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl,Substituted or unsubstituted aromatic heterocycle sulfanyl, substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -LN=S(=O)(-R, S1 )-R S2 , formula:-LS(=O)(=NR N )-R S1 , formula:-N=S(=NR N )(-R S1 )-R S2 , or the formula: -S(=NR N )2-R S1 Examples of the groups include those represented by the following formula: R 11b , R 12b , R 13b , R 14b , and R 15b Preferred embodiments of include hydrogen and halogen. R 11b , R 12b , R 13b , R 14b , and R 15b When is substituted, the substituents are each independently halogen, hydroxy, amino, alkyl, monoalkylamino, dialkylamino, an aromatic carbocyclic group, a non-aromatic carbocyclic group, an aromatic heterocyclic group, or a non-aromatic heterocyclic group.

[0038] R 11c , R 12c , R 13c , R 14c , and R 15care each independently hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted a alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic groups, substituted or unsubstituted non-aromatic carbocyclic groups, substituted or unsubstituted aromatic heterocyclic groups, substituted or unsubstituted Substituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocycle-oxy, substituted or unsubstituted non-aromatic carbocycle-oxy, substituted or unsubstituted aromatic heterocycle-oxy, substituted or unsubstituted non-aromatic heterocycle-oxy, substituted or unsubstituted aromatic carbocycle-carbonyl, substituted or unsubstituted non-aromatic carbocycle-carbonyl, substituted or unsubstituted aromatic heterocycle-carbonyl, substituted or unsubstituted non-aromatic heterocycle-carbonyl, substituted or unsubstituted aromatic carbocycle-oxycarbonyl, substituted or unsubstituted non-aromatic carbocycle-oxycarbonyl, substituted or unsubstituted aromatic heterocyclic ring-oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic ring-oxycarbonyl, substituted or unsubstituted aromatic carbocyclic ring-sulfanyl, substituted or unsubstituted non-aromatic carbocyclic ring-sulfanyl, substituted or unsubstituted aromatic heterocyclic ring-sulfanyl, substituted or unsubstituted non-aromatic heterocyclic ring-sulfanyl, substituted or unsubstituted aromatic carbocyclic ring-sulfinyl, substituted or unsubstituted non-aromatic carbocyclic ring-sulfinyl, substituted or unsubstituted aromatic heterocyclic ring-sulfinyl, substituted or unsubstituted non-aromatic heterocyclic ring-sulfinyl, substituted or unsubstituted aromatic carbocyclic ring-sulfinyl,Substituted or unsubstituted non-aromatic carbocyclic sulfonyl, substituted or unsubstituted aromatic heterocyclic sulfonyl, or substituted or unsubstituted non-aromatic heterocyclic sulfonyl. R 11c , R 12c , R 13c , R 14c , and R 15c Preferred embodiments of each independently include hydrogen, halogen, or substituted or unsubstituted alkyl. R 11c , R 12c , R 13c , R 14c , and R 15c A more preferred embodiment of the formula is hydrogen. R 11c , R 12c , R 13c , R 14c , and R 15c When is substituted, the substituents are each independently halogen, hydroxy, amino, alkyl, monoalkylamino, dialkylamino, an aromatic carbocyclic group, a non-aromatic carbocyclic group, an aromatic heterocyclic group, or a non-aromatic heterocyclic group.

[0039] R 11a and R 12a , R 12a and R 13a , R 13a and R 14a , and / or R 14a and R 15a may, together with adjacent carbon atoms, form a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted non-aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle, or a substituted or unsubstituted non-aromatic heterocycle; and / or R 11c and R 12a , R 11c and R 12c , R 12c and R 11a , R 12c and R 13a , R 12c and R 13c , R 13c and R 12a , R13c and R 14a , R 13c and R 14c , R 14c and R 13a , R 14c and R 15a , R 14c and R 15c , and / or R 15c and R 14a may be taken together with adjacent atoms to form a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle; and / or R 11a and R 13a , R 11a and R 13c , R 11a and R 14a , R 11a and R 14c , R 11a and R 15a , R 11a and R 15c , R 11c and R 13a , R 11c and R 13c , R 11c and R 14a , R 11c and R 14c , R 11c and R 15a , R 11c and R 15c , R 12a and R 14a , R 12a and R 14c , R 12a and R 15a , R 12a and R 15c , R 12c and R 14a , R 12c and R 14c , R 12c and R 15a , R 12c and R 15c , R 13a and R 15a , R 13a and R 15c , R 13c and R 15a , and / or R 13c and R 15cmay be taken together to form a C2-C4 bridge, optionally interrupted by a heteroatom; and / or R 11b and R 12b , R 11b and R 12c , R 11c and R 12b , R 11c and R 12c , R 12b and R 13b , R 12b and R 13c , R 12c and R 13b , R 12c and R 13c , R 13b and R 14b , R 13b and R 14c , R 13c and R 14b , R 13c and R 14c , R 14b and R 15b , R 14b and R 15c , R 14c and R 15b , and / or R 14c and R 15c may be taken together to form a bond.

[0040] n is an integer of 1 to 4. In a preferred embodiment, n is an integer of 1 to 3. In a more preferred embodiment, n is 1 or 2.

[0041] R S1 and R S2 are each independently hydrogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted aromatic carbocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted non-aromatic heterocyclic group, or R S1 and R S2 may be combined with the sulfur atom to form a substituted or unsubstituted non-aromatic heterocycle. R S1 and RS2 Preferred embodiments of each independently include hydrogen or substituted or unsubstituted alkyl. R S1 and R S2 A more preferred embodiment of the formula is hydrogen. R S1 and R S2 When is substituted, examples of the substituents are each independently halogen, hydroxy, amino, alkyl, alkyloxy, monoalkylamino, dialkylamino, an aromatic carbocyclic group, a non-aromatic carbocyclic group, an aromatic heterocyclic group, or a non-aromatic heterocyclic group.

[0042] R N each independently includes hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted aromatic carbocyclic groups, substituted or unsubstituted non-aromatic carbocyclic groups, substituted or unsubstituted aromatic heterocyclic groups, substituted or unsubstituted non-aromatic heterocyclic groups, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, or substituted or unsubstituted non-aromatic heterocyclic carbonyl. R N Preferred embodiments of each independently include hydrogen or substituted or unsubstituted alkyl. R N More preferred embodiments of the above are each independently substituted or unsubstituted alkyl. R N When is substituted, examples of the substituents are each independently halogen, hydroxy, amino, alkyl, alkyloxy, monoalkylamino, dialkylamino, an aromatic carbocyclic group, a non-aromatic carbocyclic group, an aromatic heterocyclic group, or a non-aromatic heterocyclic group.

[0043] Each L is independently a single bond, alkylene, or C(=O). Preferred embodiments of L each independently represent a single bond or alkylene. A more preferred embodiment of L is a single bond.

[0044] m is an integer of 1 to 5. In a preferred embodiment, m is an integer of 1 to 3. In a more preferred embodiment, m is 1 or 2.

[0045] Ring C can be an aromatic carbocycle, an aromatic heterocycle, a non-aromatic carbocycle, or a non-aromatic heterocycle. Preferred embodiments of Ring C include an aromatic carbocycle or an aromatic heterocycle. More preferred embodiments of ring C include benzene, naphthalene, indane, pyridine, pyrimidine, pyrazole, piperidine, piperazine, benzodioxole, benzothiophene, or thiazole. More preferred embodiments of ring C include benzene or pyridine. A particularly preferred embodiment of ring C is benzene.

[0046] R 5are each independently a halogen, a hydroxyl, a cyano, a carboxy, a substituted or unsubstituted carbamoyl, a substituted or unsubstituted thiocarbamoyl, a substituted or unsubstituted amidino, a substituted or unsubstituted amino, a substituted or unsubstituted ureido, a substituted or unsubstituted guanidino, a pentafluorothio, a sulfo, a substituted or unsubstituted sulfamoyl, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkyloxy, a substituted or unsubstituted alkenyloxy, a substituted or unsubstituted alkylcarbo nyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocycle-oxy, substituted or unsubstituted non-aromatic carbocycle-oxy, substituted or unsubstituted aromatic heterocycle-oxy, substituted or unsubstituted non-aromatic heterocycle-oxy, substituted or unsubstituted aromatic carbocycle-carbonyloxy, substituted or unsubstituted non-aromatic carbocycle-carbonyloxy, substituted or unsubstituted aromatic heterocycle-carbonyloxy, substituted or unsubstituted non-aromatic heterocycle ring carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl,Substituted or unsubstituted aromatic heterocycle sulfanyl, substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -LN=S(=O)(-R, S1 )-R S2 , formula:-LS(=O)(=NR N )-R S1 , formula:-N=S(=NR N )(-R S1 )-R S2 , or the formula: -S(=NR N )2-R S1 Examples of the groups include those represented by the following formula: R 5 Preferred embodiments of each independently include halogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted non-aromatic carbocyclic-oxy, or substituted or unsubstituted non-aromatic heterocyclic-oxy. R 5 More preferred embodiments of each independently include halogen, cyano, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted non-aromatic carbocyclic-oxy, or substituted or unsubstituted non-aromatic heterocyclic-oxy. R 5More preferred embodiments of each of the above are independently halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted non-aromatic carbocyclic-oxy, or substituted or unsubstituted non-aromatic heterocyclic-oxy. R 5 Particularly preferred embodiments of include halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted non-aromatic carbocyclic groups, and substituted or unsubstituted non-aromatic heterocyclic groups. R 5 When is substituted, examples of the substituent include halogen, alkyl, haloalkyl, cyanoalkyl, alkyloxyalkyl, haloalkylcarbonyl, non-aromatic carbocyclic group, non-aromatic heterocyclic group, non-aromatic carbocyclic alkyl, aromatic heterocyclic alkyl, and non-aromatic heterocyclic alkyl.

[0047] R 3a includes hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic carbocyclic groups, substituted or unsubstituted non-aromatic carbocyclic groups, substituted or unsubstituted aromatic heterocyclic groups, substituted or unsubstituted non-aromatic heterocyclic groups, substituted or unsubstituted aromatic carbocyclic group-oxy, substituted or unsubstituted non-aromatic carbocyclic group-oxy, substituted or unsubstituted aromatic heterocyclic group-oxy, substituted or unsubstituted non-aromatic heterocyclic group-oxy, substituted or unsubstituted aromatic carbocyclic group-sulfonyl, substituted or unsubstituted non-aromatic carbocyclic group-sulfonyl, substituted or unsubstituted aromatic heterocyclic group-sulfonyl, or substituted or unsubstituted non-aromatic heterocyclic group-sulfonyl. R 3a A preferred embodiment of is hydrogen. R 3aWhen is substituted, examples of the substituent include halogen, hydroxy, amino, alkyl, monoalkylamino, dialkylamino, aromatic carbocyclic groups, non-aromatic carbocyclic groups, aromatic heterocyclic groups, or non-aromatic heterocyclic groups.

[0048] R 3b includes hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic carbocyclic groups, substituted or unsubstituted non-aromatic carbocyclic groups, substituted or unsubstituted aromatic heterocyclic groups, substituted or unsubstituted non-aromatic heterocyclic groups, substituted or unsubstituted aromatic carbocyclic group-oxy, substituted or unsubstituted non-aromatic carbocyclic group-oxy, substituted or unsubstituted aromatic heterocyclic group-oxy, substituted or unsubstituted non-aromatic heterocyclic group-oxy, substituted or unsubstituted aromatic carbocyclic group-sulfonyl, substituted or unsubstituted non-aromatic carbocyclic group-sulfonyl, substituted or unsubstituted aromatic heterocyclic group-sulfonyl, or substituted or unsubstituted non-aromatic heterocyclic group-sulfonyl. R 3b A preferred embodiment of is hydrogen. R 3b When is substituted, examples of the substituent include halogen, hydroxy, amino, alkyl, monoalkylamino, dialkylamino, aromatic carbocyclic groups, non-aromatic carbocyclic groups, aromatic heterocyclic groups, or non-aromatic heterocyclic groups.

[0049] R 4a As the formula: [ka] Examples include: R 4a A more preferred embodiment of the [ka] Examples include:

[0050] R 4bExamples of the aryl group include halogen, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted aryl ... is unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic group-oxy, substituted or unsubstituted non-aromatic carbocyclic group-oxy, substituted or unsubstituted aromatic heterocyclic group-oxy, substituted or unsubstituted non-aromatic heterocyclic group-oxy, substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic heterocyclic carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic carbocyclic group-oxy nyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl,Substituted or unsubstituted aromatic heterocycle sulfanyl, substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -LN=S(=O)(-R, S1 )-R S2 , formula:-LS(=O)(=NR N )-R S1 , formula:-N=S(=NR N )(-R S1 )-R S2 , or the formula: -S(=NR N )2-R S1 Examples of the groups include those represented by the following formula: R 4b Preferred embodiments of include a substituted or unsubstituted alkyl, a substituted or unsubstituted aromatic carbocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted non-aromatic heterocyclic group. R 4b More preferred embodiments of include a substituted or unsubstituted alkyl, a substituted or unsubstituted aromatic carbocyclic group, or a substituted or unsubstituted aromatic heterocyclic group. R 4b When substituted, examples of the substituent include halogen, hydroxy, cyano, alkyl, alkenyl, haloalkyl, hydroxyalkyl, alkyloxy, haloalkyloxy, alkylsulfonyl, dialkylamino, an aromatic carbocycle which may be substituted with substituent group B, a non-aromatic carbocycle which may be substituted with substituent group B, an aromatic heterocycle which may be substituted with substituent group B, and a non-aromatic heterocycle which may be substituted with substituent group B. R 4bWhen substituted, preferred substituents include halogen, cyano, alkyl, haloalkyl, hydroxyalkyl, alkyloxy, haloalkyloxy, alkylsulfonyl, aromatic carbocycle optionally substituted with substituent group B, non-aromatic carbocycle optionally substituted with substituent group B, aromatic heterocycle optionally substituted with substituent group B, non-aromatic heterocycle optionally substituted with substituent group B, aromatic carbocycle-oxy optionally substituted with substituent group B, non-aromatic carbocycle-oxy optionally substituted with substituent group B, aromatic heterocycle-oxy optionally substituted with substituent group B, and non-aromatic heterocycle-oxy optionally substituted with substituent group B.

[0051] L 3 Examples of the alkyl group include a single bond or substituted or unsubstituted alkylene. L 3 A preferred embodiment of is a single bond, unsubstituted alkylene, or alkylene substituted with halogen. L 3 Preferred specific embodiments of the formula include a single bond, methylene, or the formula: [ka] Examples include:

[0052] R 7Examples of the aryl group include hydrogen, halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcapryloxy, and the like. carboxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted Substituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocycle-oxy, substituted or unsubstituted non-aromatic carbocycle-oxy, substituted or unsubstituted aromatic heterocycle-oxy, substituted or unsubstituted non-aromatic heterocycle-oxy, substituted or unsubstituted aromatic carbocycle-carbonyloxy, substituted or unsubstituted non-aromatic carbocycle-carbonyloxy, substituted or unsubstituted aromatic heterocycle-carbonyloxy, substituted or unsubstituted non-aromatic heterocycle-carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl, substituted or unsubstituted aromatic heterocyclic sulfanyl,Substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -N=S(=O)(-R, S1 )-R S2 , formula:-S(=O)(=NR N )-R S1 , formula:-N=S(=NR N )(-R S1 )-R S2 , or the formula: -S(=NR N )2-R S1 Examples of the groups include those represented by the following formula: R 7 Preferred embodiments of the formula include halogen, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic heterocyclic groups, substituted or unsubstituted non-aromatic heterocyclic groups, and the formula: -S(=O)(=NR N )-R S1 Examples of the groups include those represented by the following formula: R 7 When is substituted, examples of the substituents include oxo, halogen, cyano, hydroxy, alkyl, haloalkyl, alkyloxy, haloalkyloxy, hydroxyalkyl, alkylcarbonyl, or alkylsulfonyl.

[0053] R 6are each independently a halogen, a hydroxyl, a cyano, a carboxy, a substituted or unsubstituted carbamoyl, a substituted or unsubstituted thiocarbamoyl, a substituted or unsubstituted amidino, a substituted or unsubstituted amino, a substituted or unsubstituted ureido, a substituted or unsubstituted guanidino, a pentafluorothio, a sulfo, a substituted or unsubstituted sulfamoyl, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkyloxy, a substituted or unsubstituted alkenyloxy, a substituted or unsubstituted alkylcarbo nyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocycle-oxy, substituted or unsubstituted non-aromatic carbocycle-oxy, substituted or unsubstituted aromatic heterocycle-oxy, substituted or unsubstituted non-aromatic heterocycle-oxy, substituted or unsubstituted aromatic carbocycle-carbonyloxy, substituted or unsubstituted non-aromatic carbocycle-carbonyloxy, substituted or unsubstituted aromatic heterocycle-carbonyloxy, substituted or unsubstituted non-aromatic heterocycle ring carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl,Substituted or unsubstituted aromatic heterocycle sulfanyl, substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -LN=S(=O)(-R, S1 )-R S2 , formula:-LS(=O)(=NR N )-R S1 , formula:-N=S(=NR N )(-R S1 )-R S2 , or the formula: -S(=NR N )2-R S1 Examples of the groups include those represented by the following formula: R 6 Preferred embodiments of each independently include halogen, cyano, hydroxy, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted non-aromatic carbocyclic oxy, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted non-aromatic carbocyclic sulfonyl, or substituted or unsubstituted non-aromatic heterocyclic sulfonyl. R 6 More preferred embodiments of the above are each independently halogen, or substituted or unsubstituted alkyloxy. R 6 More preferred embodiments of the above are each independently halogen or haloalkyloxy. R 6In the case where the group is substituted, examples of the substituent include halogen, alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkyloxy, haloalkyloxy, alkyloxyalkyl, haloalkylcarbonyl, alkyloxycarbonylalkyl, an aromatic carbocyclic group which may be substituted with substituent group B, a non-aromatic carbocyclic group which may be substituted with substituent group B, an aromatic heterocyclic group which may be substituted with substituent group B, a non-aromatic heterocyclic group which may be substituted with substituent group B, an aromatic carbocyclic oxy which may be substituted with substituent group B, a non-aromatic carbocyclic oxy which may be substituted with substituent group B, an aromatic heterocyclic oxy which may be substituted with substituent group B, and a non-aromatic heterocyclic oxy which may be substituted with substituent group B.

[0054] R 16Examples of the alkyl group include hydrogen, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, Substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic groups, substituted or unsubstituted non-aromatic carbocyclic groups, substituted or unsubstituted aromatic heterocyclic groups, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocycle-oxy, substituted or unsubstituted non-aromatic carbocycle-oxy, substituted or unsubstituted aromatic heterocycle-oxy, substituted or unsubstituted non-aromatic heterocycle-oxy, substituted or unsubstituted aromatic carbocycle-carbonyl, substituted or unsubstituted non-aromatic carbocycle-carbonyl, substituted or unsubstituted aromatic heterocycle-carbonyl, substituted or unsubstituted non-aromatic heterocycle-carbonyl, substituted or unsubstituted aromatic carbocycle-oxycarbonyl, substituted or unsubstituted non-aromatic carbocycle-oxycarbonyl, substituted or unsubstituted aromatic hetero ring oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl, substituted or unsubstituted aromatic heterocyclic sulfanyl, substituted or unsubstituted non-aromatic heterocyclic sulfanyl, substituted or unsubstituted aromatic carbocyclic sulfinyl, substituted or unsubstituted non-aromatic carbocyclic sulfinyl, substituted or unsubstituted aromatic heterocyclic sulfinyl, substituted or unsubstituted non-aromatic heterocyclic sulfinyl, substituted or unsubstituted aromatic carbocyclic sulfonyl,Examples of the sulfonyl include substituted or unsubstituted non-aromatic carbocyclic sulfonyl, substituted or unsubstituted aromatic heterocyclic sulfonyl, and substituted or unsubstituted non-aromatic heterocyclic sulfonyl. R 16 Preferred embodiments of include substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, or substituted or unsubstituted non-aromatic heterocyclic carbonyl. R 16 Preferred embodiments of include substituted or unsubstituted alkyl, an aromatic carbocyclic group which may be substituted with substituent group B, a non-aromatic carbocyclic group which may be substituted with substituent group B, an aromatic heterocyclic group which may be substituted with substituent group B, a non-aromatic heterocyclic group which may be substituted with substituent group B, an aromatic carbocyclic carbonyl which may be substituted with substituent group B, a non-aromatic carbocyclic carbonyl which may be substituted with substituent group B, an aromatic heterocyclic carbonyl which may be substituted with substituent group B, or a non-aromatic heterocyclic carbonyl which may be substituted with substituent group B. R 16 Particularly preferred embodiments of the formula (I) include aromatic carbocyclic groups which may be substituted with the substituent group B. R 16 When substituted, examples of the substituent include halogen, alkyl, haloalkyl, an aromatic carbocyclic group which may be substituted with substituent group B, a non-aromatic carbocyclic group which may be substituted with substituent group B, an aromatic heterocyclic group which may be substituted with substituent group B, and a non-aromatic heterocyclic group which may be substituted with substituent group B.

[0055] The feature of the compound according to the present invention is that it has MGAT2 inhibitory effect by being made into a dihydropyrazolopyrazinone derivative represented by formula (I). Another feature is that the dihydropyrazolopyrazinone derivative represented by formula (I) has a structure in which a pyrazole ring is condensed to a dihydropyrazinone ring, and thus the enone structure can be avoided, and toxicity can be suppressed. Another feature of the dihydropyrazolopyrazinone derivative represented by formula (I) is that it has high solubility and metabolic stability, and is highly stable in acidic solution.

[0056] The compounds represented by formula (I) are not limited to any particular isomer, and include all possible isomers (e.g., keto-enol isomers, imine-enamine isomers, diastereoisomers, optical isomers, rotamers, etc.), racemates, or mixtures thereof.

[0057] One or more hydrogen, carbon and / or other atoms of the compounds of formula (I) may be replaced with isotopes of the hydrogen, carbon and / or other atoms, respectively. Examples of such isotopes include, for example, 2 H, 3 H, 11 C. 13 C. 14 C. 15 N, 18 O. 17 O. 31 P, 32 P, 35 S, 18 F, 123 I and 36 As Cl, hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine and chlorine are included. The compounds of formula (I) also include compounds substituted with such isotopes. The compounds substituted with such isotopes are also useful as pharmaceuticals, and include all radiolabeled compounds of the compounds of formula (I). The present invention also includes a "radiolabeling method" for producing the "radiolabeled compound", and the "radiolabeled compound" is useful as a research and / or diagnostic tool in metabolism pharmacokinetic studies, binding assays.

[0058] Radiolabeled compounds of formula (I) can be prepared by methods well known in the art. For example, tritium-labeled compounds of formula (I) can be prepared by introducing tritium into a particular compound of formula (I) through catalytic dehalogenation reaction with tritium. This method involves reacting a suitable halogen-substituted precursor of the compound of formula (I) with tritium gas in the presence of a suitable catalyst, such as Pd / C, in the presence or absence of a base. Other suitable methods for preparing tritium-labeled compounds can be found in "Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A), Chapter 6 (1987)". 14 C-labeled compounds are 14 It can be prepared by using a raw material having C carbon.

[0059] Examples of pharma- ceutically acceptable salts of the compound represented by formula (I) include salts of the compound represented by formula (I) and alkali metals (e.g., lithium, sodium, potassium, etc.), alkaline earth metals (e.g., calcium, barium, etc.), magnesium, transition metals (e.g., zinc, iron, etc.), ammonia, organic bases (e.g., trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, ethylenediamine, pyridine, etc.), and the like. lysine, picoline, quinoline, etc.) and amino acids, or inorganic acids (e.g., hydrochloric acid, sulfuric acid, nitric acid, carbonic acid, hydrobromic acid, phosphoric acid, hydroiodic acid, etc.) and organic acids (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, ascorbic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, etc.). In particular, salts with hydrochloric acid, sulfuric acid, phosphoric acid, tartaric acid, methanesulfonic acid, etc. may be mentioned. These salts can be formed by conventional methods.

[0060] The compound represented by formula (I) or a pharma- ceutically acceptable salt thereof of the present invention may form a solvate (e.g., hydrate, etc.), cocrystal, and / or crystalline polymorph, and the present invention also includes such various solvates, cocrystals, and crystalline polymorphs. A "solvate" may be coordinated with any number of solvent molecules (e.g., water molecules, etc.) to the compound represented by formula (I). When the compound represented by formula (I) or a pharma- ceutically acceptable salt thereof is left in the air, it may absorb moisture, and adsorbed water may adhere to the compound or a hydrate may be formed. In addition, the compound represented by formula (I) or a pharma- ceutically acceptable salt thereof may be recrystallized to form a crystalline polymorph. A "cocrystal" means that the compound represented by formula (I) or a salt thereof and a counter molecule are present in the same crystal lattice, and may be formed with any number of counter molecules.

[0061] The compound of the present invention represented by formula (I) or a pharma- ceutically acceptable salt thereof may form a prodrug, and the present invention also includes such various prodrugs. A prodrug is a derivative of the compound of the present invention having a group capable of being chemically or metabolically decomposed, and is a compound that becomes a pharma- cetically active compound of the present invention in vivo by solvolysis or under physiological conditions. Prodrugs include compounds that are converted to the compound represented by formula (I) by enzymatic oxidation, reduction, hydrolysis, etc. under physiological conditions in vivo, and compounds that are converted to the compound represented by formula (I) by hydrolysis by gastric acid, etc. Methods for selecting and producing suitable prodrug derivatives are described, for example, in "Design of Prodrugs, Elsevier, Amsterdam, 1985". Prodrugs may themselves have activity.

[0062] When the compound represented by formula (I) or a pharma- ceutically acceptable salt thereof has a hydroxyl group, examples of the prodrug include acyloxy derivatives and sulfonyloxy derivatives produced by reacting a compound having a hydroxyl group with a suitable acyl halide, a suitable acid anhydride, a suitable sulfonyl chloride, a suitable sulfonyl anhydride, and a mixed anhydride, or by reacting the compound using a condensing agent. For example, CH3COO-, C2H5COO-, tert-BuCOO-, C 15 H 31 Examples include COO-, PhCOO-, (m-NaOOCPh)COO-, NaOOCCH2CH2COO-, CH3CH(NH2)COO-, CH2N(CH3)2COO-, CH3SO3-, CH3CH2SO3-, CF3SO3-, CH2FSO3-, CF3CH2SO3-, p-CH3O-PhSO3-, PhSO3-, and p-CH3PhSO3-.

[0063] (Method for producing the compound of the present invention) The compound of the present invention represented by formula (I) can be produced, for example, by the general synthesis method shown below. Extraction, purification, etc. may be carried out by the treatments carried out in ordinary organic chemistry experiments. The compounds of the present invention can be synthesized with reference to techniques known in the art.

[0064] (General synthesis method) The compound represented by formula (I) according to the present invention (a17 below) can be produced, for example, by the following process. [ka] (In the formula, each symbol has the same meaning as defined above.) Process A-1 Compound a2 can be obtained by reacting compound a1 with tert-butylsulfinamide and tetraisopropoxytitanium, tetraethoxyethane, or the like. The reaction temperature is 20°C to 120°C, preferably 70°C to 100°C. The reaction time is 1 to 12 hours, preferably 3 to 6 hours. Examples of the reaction solvent include tetrahydrofuran, 2-methyltetrahydrofuran, toluene, and the like. Process A-2 Compound A4 can be obtained by reacting a3 with a base such as lithium diisopropylamide or lithium hexamethyldisilazide, and then adding titanium triisopropoxide chloride or the like as necessary, and reacting with compound A2. Examples of R in compound a3 include methyl, ethyl, and tert-butyl. The reaction temperature for the reaction of ester a3 with a base such as lithium diisopropylamide or lithium hexamethyldisilazide and the subsequent reaction with compound a2 is -78°C to -20°C. The reaction time of the base with ester a3 is 30 minutes to 2 hours, and the subsequent reaction with compound a2 is 1 to 5 hours. Reaction solvents include tetrahydrofuran, diethyl ether and the like. Process A-3 Compound a5 can be obtained by reacting compound a4 with an acid or Lewis acid and then reacting it with Boc2O in the presence of a base. Examples of the acid include hydrochloric acid-ethyl acetate, hydrochloric acid-methanol, hydrochloric acid-dioxane, sulfuric acid, formic acid, trifluoroacetic acid, etc. Examples of the Lewis acid include trimethylsilyl iodide, BBr3, AlCl3, BF3·(Et2O), etc., and 1 to 10 molar equivalents can be used relative to compound a4. Examples of the base include sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, calcium carbonate, cesium carbonate, pyridine, triethylamine, etc., and can be used in an amount of 3 to 15 molar equivalents relative to compound a4. The reaction temperature is 0°C to 60°C, preferably 0°C to 20°C. The reaction time is 0.5 to 24 hours, preferably 6 to 18 hours. Examples of reaction solvents include methanol, ethanol, water, acetone, acetonitrile, DMF, etc., and these can be used alone or in combination. Process A-4 Compound a6 can be obtained by reacting compound a5 with a reducing agent. The reducing agent includes lithium borohydride, lithium aluminum hydride, etc., and can be used in an amount of 1 to 10 molar equivalents relative to compound a5. The reaction temperature is from 0° C. to the reflux temperature, preferably from 20° C. to the reflux temperature. The reaction time is 0.2 to 48 hours, preferably 1 to 24 hours. Examples of the reaction solvent include methanol, ethanol, propanol, isopropanol, butanol, tetrahydrofuran, diethyl ether, dichloromethane, water, etc., and these can be used alone or in combination. Process A-5 Compound a7 can be obtained by reacting compound a6 with an oxidizing agent such as 2-iodoxybenzoic acid or Dess-Martin periodinane. The reaction temperature is -10°C to 50°C, preferably 0°C to 30°C. The reaction time is 1 hour to 24 hours, preferably 5 hours to 20 hours. As the reaction solvent, dimethyl sulfoxide or the like can be used. Process A-6 Compound a8 can be obtained by reacting compound a7 with osmium tetroxide, 4-methylmorpholine, 4-methylmorpholine N-oxide, sodium periodate, or the like. The reaction temperature is -10°C to 50°C, preferably 0°C to 30°C. The reaction time is 1 hour to 24 hours, preferably 5 hours to 20 hours. As the reaction solvent, a mixed solvent of acetone and water, etc. can be used. Process A-7 Compound a10 can be obtained by reacting compound a8 with nucleophile a9. Examples of the nucleophile a9 include lithium reagents such as methyllithium and ethyllithium, Grignard reagents such as methylmagnesium bromide, methylmagnesium chloride, methylmagnesium iodide, ethylmagnesium bromide, ethylmagnesium chloride, and ethylmagnesium iodide, and mixed reagents of these with metal salts. The nucleophile a9 can be used in an amount of 1 to 5 molar equivalents relative to compound a8. The reaction temperature is from -78°C to the reflux temperature of the solvent, preferably from -45°C to 0°C. The reaction time is 0.5 to 24 hours, preferably 1 to 6 hours. Examples of reaction solvents include tetrahydrofuran, hexane, diethyl ether, methyl tert-butyl ether, toluene, dichloromethane, methanol, etc., and these can be used alone or in combination. Nucleophiles a9 can be prepared by lithiation of the halide with an alkyllithium such as n-butyllithium. The reaction solvent is not particularly limited as long as it is a solvent that does not react with alkyllithium, such as tetrahydrofuran, dioxane, etc. The temperature of the lithiation reaction is preferably about -78°C to 0°C. In addition, by using a reducing agent such as sodium borohydride, lithium borohydride, or lithium aluminum hydride instead of the nucleophilic agent a9, R 3b It is possible to obtain a compound in which is hydrogen. Process A-8 Compound a11 can be obtained by reacting compound a10 with thionyl chloride and a base. The base includes pyridine, triethylamine, etc., and can be used in an amount of 1 to 5 molar equivalents relative to compound a10. The reaction temperature is -10°C to 50°C, preferably 0°C to 30°C. The reaction time is 1 hour to 24 hours, preferably 5 hours to 10 hours. As the reaction solvent, acetonitrile, dioxane, tetrahydrofuran, DMF, etc. can be used. Process A-9 Compound A12 can be obtained by reacting compound A11 with ruthenium chloride hydrate, sodium periodate, or the like. The reaction temperature is -10°C to 50°C, preferably 0°C to 30°C. The reaction time is 1 hour to 24 hours, preferably 5 hours to 20 hours. As the reaction solvent, a mixed solvent of ethyl acetate and water, etc. can be used. Process A-10 Compound a14 can be obtained by reacting compound a12, compound a13 and a base. Examples of the base include sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, calcium carbonate, cesium carbonate, pyridine, triethylamine, etc., and can be used in an amount of 1 to 5 molar equivalents relative to compound a13. The reaction temperature is from 0°C to 150°C, preferably from 50°C to 100°C. The reaction time is 0.5 to 24 hours, preferably 1 to 5 hours. Examples of reaction solvents include methanol, ethanol, acetonitrile, DMF, etc., and these can be used alone or in combination. Process A-11 Compound a15 can be obtained by reacting compound a14 with a base. The base includes sodium hydroxide, potassium hydroxide, sodium hydride, etc., and can be used in an amount of 1 to 5 molar equivalents relative to compound a14. The reaction temperature is from 0°C to 100°C, preferably from 0°C to 30°C. The reaction time is 0.5 to 24 hours, preferably 1 to 5 hours. Examples of reaction solvents include methanol, ethanol, acetonitrile, water, DMF, etc., and these can be used alone or in combination. Process A-12 Compound a16 can be obtained by reacting compound a15 with an acid or Lewis acid. Examples of the acid include hydrochloric acid-ethyl acetate, hydrochloric acid-methanol, hydrochloric acid-dioxane, sulfuric acid, formic acid, trifluoroacetic acid, etc. Examples of the Lewis acid include trimethylsilyl iodide, BBr3, AlCl3, BF3·(Et2O), etc., and can be used in an amount of 1 to 50 molar equivalents relative to compound a15. The reaction temperature is 0°C to 60°C, preferably 0°C to 20°C. The reaction time is 0.5 to 24 hours, preferably 6 to 18 hours. Examples of reaction solvents include ethyl acetate, methanol, ethanol, water, acetone, acetonitrile, DMF, etc., and these can be used alone or in combination. Process A-13 Compound a17 can be obtained by reacting compound a16 with a condensing agent and a base. Examples of the condensing agent include dicyclohexylcarbodiimide, carbonyldiimidazole, dicyclohexylcarbodiimide-N-hydroxybenzotriazole, EDC, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride, and HATU, and can be used in an amount of 1 to 5 molar equivalents relative to compound a16. The base includes triethylamine, diisopropylethylamine and the like, which can be used in an amount of 1 to 5 molar equivalents based on compound a16. The reaction temperature is -20°C to 60°C, preferably 0°C to 30°C. The reaction time is 0.1 to 24 hours, preferably 1 to 5 hours. Examples of reaction solvents include DMF, DMA, NMP, tetrahydrofuran, dioxane, dichloromethane, acetonitrile, etc., and these can be used alone or in combination.

[0065] The compound according to the present invention has an MGAT2 inhibitory effect and is useful as a preventive or therapeutic agent for obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, hyperfatty acidemia, diabetes, arteriosclerosis, and the like. The compound of the present invention has not only an MGAT2 inhibitory effect but also pharmaceutical utility, and has any or all of the following excellent characteristics: a) High metabolic stability. b) It has high solubility. c) There is little concern about phototoxicity. d) There is little concern about liver toxicity. e) There is little concern about nephrotoxicity. f) There is little concern about toxicity to the cardiovascular system. g) There is less concern about gastrointestinal disorders. h) There is little concern about drug interactions. i) High oral absorbability. j) Small clearance. k) High transferability to target tissues. l) Strong enzymatic activity. m) There is little induction of drug metabolizing enzymes. n) It has strong medicinal properties. o) High selectivity of MGAT2 inhibitory action. p)High chemical stability.

[0066] The pharmaceutical composition of the present invention can be administered orally or parenterally, including transdermal, subcutaneous, intravenous, intraarterial, intramuscular, intraperitoneal, transmucosal, inhalation, nasal, ocular, otic, vaginal, etc.

[0067] In the case of oral administration, the composition may be prepared and administered in any of the commonly used dosage forms, such as solid preparations for internal use (e.g., tablets, powders, granules, capsules, pills, films, etc.), liquid preparations for internal use (e.g., suspensions, emulsions, elixirs, syrups, lemonades, spirits, aromatic perfumes, extracts, decoctions, tinctures, etc.), etc., in accordance with the usual methods. Tablets may be sugar-coated tablets, film-coated tablets, enteric-coated tablets, sustained-release tablets, troches, sublingual tablets, buccal tablets, chewable tablets, or orally disintegrating tablets, powders and granules may be dry syrups, and capsules may be soft capsules, microcapsules, or sustained-release capsules.

[0068] In the case of parenteral administration, the compound can be suitably administered in any of the commonly used dosage forms, such as injections, drops, external preparations (e.g., eye drops, nasal drops, ear drops, aerosols, inhalants, lotions, injections, liniments, mouthwashes, enemas, ointments, plasters, jellies, creams, patches, poultices, external powders, suppositories, etc.) The injections may be emulsions such as O / W, W / O, O / W / O, and W / O / W types.

[0069] A pharmaceutical composition can be prepared by mixing an effective amount of the compound of the present invention with various pharmaceutical additives such as excipients, binders, disintegrants, and lubricants suitable for the dosage form as necessary. Furthermore, the pharmaceutical composition can be prepared as a pharmaceutical composition for children, elderly people, critically ill patients, or surgical patients by appropriately changing the effective amount of the compound of the present invention, the dosage form, and / or various pharmaceutical additives. The pharmaceutical composition for children is preferably administered to patients under 12 or 15 years old. The pharmaceutical composition for children can be administered to patients under 27 days after birth, 28 days to 23 months after birth, 2 years to 11 years old, or 12 years to 16 years or 18 years old. The pharmaceutical composition for the elderly is preferably administered to patients over 65 years old.

[0070] The dosage of the pharmaceutical composition of the present invention is desirably set in consideration of the age and body weight of the patient, the type and severity of the disease, the administration route, etc., but in the case of oral administration, it is usually 0.05 to 100 mg / kg / day, preferably 0.1 to 10 mg / kg / day. In the case of parenteral administration, it varies greatly depending on the administration route, but it is usually 0.005 to 10 mg / kg / day, preferably 0.01 to 1 mg / kg / day. This may be administered once or in divided doses several times a day.

[0071] The dosage of the concomitant drug can be appropriately selected based on the clinically used dosage. The compounding ratio of the compound of the present invention to the concomitant drug can be appropriately selected depending on the administration subject, administration route, target disease, symptoms, combination, etc. For example, when the administration subject is a human, 0.01 to 100 parts by weight of the concomitant drug may be used per part by weight of the compound of the present invention.

[0072] The pharmaceutical composition of the present invention is for use in patients with obesity (including those who have both type 2 diabetes and dyslipidemia and whose BMI is less than 25 kg / m despite diet and exercise therapy). 2 This is also valid for the above cases.

[0073] The pharmaceutical composition of the present invention is also effective for severe obesity for which previous dietary and exercise therapies have not been effective enough.

[0074] The pharmaceutical composition of the present invention can also be used in combination with other anti-obesity drugs (pharmaceutical compositions containing a compound having an anti-obesity effect, drugs that can be used for obesity or weight management in obesity, etc.). For example, a pharmaceutical composition containing a compound having an anti-obesity effect can be used in combination with the compound of the present invention for the prevention and / or treatment of obesity, weight management in obesity, etc. In addition, a pharmaceutical composition containing the compound of the present invention can be used in combination with a pharmaceutical composition containing a compound having an anti-obesity effect for the prevention and / or treatment of obesity, weight management in obesity, etc. In addition, the administration therapy of the pharmaceutical composition of the present invention can also be used in combination with diet therapy, drug therapy, exercise, etc.

[0075] The abbreviations used in this specification have the following meanings. Boc: tert-butoxycarbonyl DMA: Dimethylacetamide DMF: N,N-dimethylformamide DMSO: Dimethyl sulfoxide EDC: 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide Et: Ethyl HATU: O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate NMP: N-methylpyrrolidone

[0076] The present invention will be described in more detail below with reference to examples and test examples, but the present invention is not limited to these. The NMR spectrum data of the compound of the present invention and its intermediates are shown below. The NMR analysis obtained in each example was performed at 400 MHz, and was measured using deuterated chloroform (CDCl3) or dimethyl sulfoxide (d6-DMSO). EXAMPLES

[0077] [ka] Step 1 Synthesis of compound 2 (R)-2-methylpropane-2-sulfinamide (631 mg, 5.21 mmol) was dissolved in toluene (2.5 mL) and tetraethoxytitanium (0.654 mL, 3.12 mmol) was added. Then, known compound 1 (384 mg, 2.08 mmol) was dissolved in toluene (2.5 mL) and added, and the mixture was stirred at 100° C. for 3 hours. Then, at room temperature, an aqueous citric acid solution and ethyl acetate were added, and the insoluble matter was filtered and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain compound 2 (428 mg, 72% yield). 1 H-NMR (CDCl3) δ: 1.32 (s, 9H), 3.31-3.38 (m, 1H), 3.45-3.52 (m, 1H), 4.27-4.33 (m, 1H), 4.36-4.41 (m, 1H), 6.43-6.49 (m, 2H). Step 2 Synthesis of compound 3 To a 1M solution of lithium hexamethyldisilazide in tetrahydrofuran (2.23mL, 2.23mmol), tetrahydrofuran (1mL) and methyl acetate (0.178mL, 2.23mmol) were added at -78°C and stirred for 1 hour. Then, a 1M solution of titanium triisopropoxide chloride in hexane (2.98mL, 2.98mmol) was added dropwise at -78°C and stirred for 30 minutes. Then, compound 2 (428mg, 1.49mmol) was dissolved in tetrahydrofuran (1mL) and added dropwise at -78°C and stirred for 4 hours. Then, 10% aqueous citric acid solution and Rochelle salt were added, and the mixture was heated to room temperature and stirred for 12 hours. Then, the mixture was extracted with ethyl acetate, and the organic layer was washed with saturated sodium bicarbonate water and saturated aqueous sodium chloride solution, and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain compound 3 (305mg, yield 57%). 1H-NMR (CDCl3) δ: 1.22 (s, 9H), 2.19-2.27 (m, 1H), 2.45-2.49 (m, 1H), 2.74 (d, J = 15.9 Hz, 1H), 3.40 (d, J = 15.9 Hz, 1H), 3.70 (s, 3H), 4.19-4.24 (m, 1H), 4.51-4.57 (m, 1H), 5.02 (s, 1H), 6.36-6.47 (m, 2H). Step 3 Synthesis of compound 4 Compound 3 (2.31 g, 6.40 mmol) was dissolved in methanol (18.5 mL), 4 mol / L hydrochloric acid dioxane solution (3.20 mL, 12.8 mmol) was added, and the mixture was stirred at room temperature for 1 hour and 15 minutes. The mixture was diluted with water (9.3 mL), sodium bicarbonate (1.61 g, 19.2 mmol) and di-tert-butyl dicarbonate (2.79 g, 12.8 mmol) were added, and the mixture was stirred at room temperature for another 18 hours. The reaction solution was concentrated under reduced pressure, and then azeotropically dehydrated with ethyl acetate, and then diluted with ethyl acetate to filter insoluble matter. The solvent was removed under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate, silica gel) to obtain compound 4 (1.85 g, purity 96.1%, yield 78%). 1 H-NMR (CDCl3) δ: 6.42-6.33 (2H, m), 5.50 (1H, s), 4.27-4.13 (2H, m), 3.64 (3H, s), 3.37-3.30 (1H, m), 3.04 (1H, d, J = 14.6 Hz), 2.91-2.82 (1H, m), 2.27-2.18 (1H, m), 1.38 (9H, br s). Step 4 Synthesis of compound 5 Compound 4 (1.85 g, 4.97 mmol) was dissolved in tetrahydrofuran (9.3 mL), and a 1 mol / L tetrahydrofuran solution of lithium borohydride (2.50 ml, 2.50 mmol) was added at -78°C, followed by stirring at room temperature for 18.5 hours. Ice was added to the reaction solution, and a 2 mol / L aqueous hydrochloric acid solution was added to adjust the pH to 4, followed by extraction with ethyl acetate. The solvent was distilled off under reduced pressure, and the resulting residue was dissolved in dimethyl sulfoxide (9.1 mL), and 2-iodoxybenzoic acid (2.09 g, 7.46 mmol) was added and stirred at room temperature for 19.5 hours, after which 2-iodoxybenzoic acid (0.418 g, 1.41 mmol) was added and stirred for 4 hours. Ethyl acetate and water were added to the reaction solution, the precipitated solid was filtered off, the organic layer was washed with water, and the solvent was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate, silica gel) to obtain compound 5 (1.70 g, purity 94.4%, yield 99%). 1 H-NMR (CDCl3) δ: 9.65 (1H, q, J = 1.7 Hz), 6.45-6.36 (2H, m), 5.03 (1H, s), 4.23 (1H, tt, J = 11.3, 4.0 Hz), 4.18 (1H, td, J = 11.3, 2.3 Hz), 3.59-3.51 (1H, m), 3.34 (1H, dt, J = 17.1, 1.7 Hz), 2.96-2.88 (1H, m), 2.19 (1H, ddd, J = 14.2, 10.9, 4.1 Hz), 1.42 (9H, s). Step 5 Synthesis of compound 6 Compound 5 (1.70 g, 4.89 mmol) was dissolved in acetone (30 mL) and water (3 mL), and 5% microencapsulated osmium tetroxide (0.889 g, 0.245 mmol), 4-methylmorpholine (1.24 g, 12.2 mmol), 4-methylmorpholine N-oxide (1.15 g, 9.79 mmol), and sodium periodate (6.07 g, 24.5 mmol) were added and stirred at room temperature for 15 hours. The reaction solution was concentrated under reduced pressure, diluted with ethyl acetate and water, and sodium thiosulfate pentahydrate (6.07 g, 24.5 mmol) was added. Insoluble matter was filtered off, the organic layer was washed with water, and the solvent was distilled off under reduced pressure. The resulting residue was dissolved in methanol (12 mL), sodium borohydride (93.0 mg, 2.45 mmol) was added, and the mixture was stirred at room temperature for 20 minutes. The reaction solution was concentrated under reduced pressure, diluted with water, and then 2 mol / L aqueous hydrochloric acid was added to adjust the pH to 4, followed by extraction with ethyl acetate. The organic layer was washed with water, and the solvent was removed under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate, silica gel) to obtain compound 6 (1.06 g, yield 68%). 1 H-NMR (CDCl3) δ: 6.43-6.37 (2H, m), 5.17 (1H, s), 4.49-4.44 (1H, m), 4.28-4.14 (3H, m), 3.70 (1H, dd, J = 11.4, 10.1 Hz), 2.51-2.36 (2H, m), 1.42 (9H, s). Step 6 Synthesis of compound 7 A solution of compound 6 (1.05g, 3.32mmol) in acetonitrile (12mL) was added dropwise to a solution of thionyl chloride (1.22g, 10.3mmol) in acetonitrile (10mL) at -50℃, and after stirring at the same temperature for 1 hour, pyridine (1.05g, 23.3mmol) was added and stirred at room temperature for 3 hours. After dilution with water, it was extracted with ethyl acetate, washed with water, and the solvent was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate, silica gel) to obtain compound 7 (1.09g, purity 91.2%, yield 83%) as a mixture of diastereomers with a ratio of 92.6 to 7.4. Both diastereomers were used in the next step without separation. Step 7 Synthesis of compound 8 Compound 7 (1.08 g, 2.73 mmol) was dissolved in ethyl acetate (10 mL) and water (10 mL), and ruthenium chloride hydrate (3.0 mg, 0.01 mmol) and sodium periodate (642 mg, 3.00 mmol) were added at 0°C, and the mixture was stirred at room temperature for 2 hours. Water (10 mL) was added at room temperature, and ruthenium chloride hydrate (2.1 mg, 0.01 mmol) and sodium periodate (117 mg, 0.546 mmol) were added, and the mixture was stirred at room temperature for another 3 hours. The mixture was extracted with ethyl acetate, washed with water, and then filtered through a column packed with dried silica gel. The filtrate was concentrated under reduced pressure and then powdered with hexane-ethyl acetate to obtain compound 8 (873 mg, 85% yield). 1 H-NMR (DMSO-D6) δ: 6.93 (1H, ddd, J = 11.4, 9.2, 2.7 Hz), 6.72 (1H, dt, J = 10.1, 2.0 Hz), 5.09 (1H, d, J = 10.2 Hz), 4.63 (1H, dd, J = 10.2, 1.0 Hz), 4.42 (1H, ddd, J = 12.2, 4.0, 2.6 Hz), 4.22 (1H, td, J = 12.4, 2.0 Hz), 2.47-2.32 (2H, m), 1.22 (9H, s). Step 8 Synthesis of compound 10 Compound 9 (110 mg, 0.439 mmol) was dissolved in DMF (4 mL), potassium carbonate (60.6 mg, 0.439 mmol) was added, and the mixture was heated to 100°C. Compound 8 (151 mg, 0.399 mmol) was added and the mixture was stirred at 100°C for 40 minutes. After dilution with water, the mixture was extracted with ethyl acetate, washed with water, and the solvent was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate, silica gel) to obtain compound 10 (151 mg, purity 96.3%, yield 67%). 1 H-NMR (CDCl3) δ: 8.42 (1H, d, J = 2.8 Hz), 8.01-7.95 (1H, m), 7.46 (1H, td, J = 8.5, 2.8 Hz), 6.84 (1H, s), 6.44-6.32 (2H, m), 5.87 (2H, s), 5.15-4.86 (2H, m), 4.44-4.19 (4H, m), 2.68-2.91 (1H, m),1.90-1.81 (1H, m), 1.42 (3H, t, J = 7.2 Hz), 1.32 (9H, br s). Step 9 Synthesis of compound 11 Compound 10 (150 mg, 0.439 mmol) was dissolved in DMF (4 mL), 60% sodium hydride (42.3 mg, 1.06 mmol) was added, and the mixture was stirred at room temperature for 1 hour. After dilution with ice, 1 mol / L aqueous hydrochloric acid was added to adjust the pH to 4, and the mixture was extracted with ethyl acetate. After washing with water, the solvent was concentrated under reduced pressure, and 4 mol / L hydrochloric acid dioxane (4 mL, 16.0 mmol) was added to the resulting residue and stirred at room temperature for 1 hour. The solvent was concentrated under reduced pressure, diluted with DMF (6 mL), and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (151 mg, 0.398 mmol) and triethylamine (0.257 mL, 1.86 mmol) were added, and the mixture was stirred at room temperature for 30 minutes. Water was added, and the mixture was extracted with ethyl acetate. After washing with water, the solvent was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate, silica gel) to obtain compound 11 (59.5 mg, purity 97.4%, yield 55%). 1 H-NMR (CDCl3) δ: 8.43 (1H, d, J = 2.9 Hz), 7.96 (1H, dd, J = 8.9, 4.5 Hz), 7.45 (1H, td, J = 8.6, 2.9 Hz), 6.54-6.49 (2H, m), 5.75 (1H, s), 5.68 (2H, s), 4.77 (1H, d, J = 13.1 Hz), 4.29-4.19 (3H, m), 2.37-2.21 (2H, m). Step 10 Synthesis of compound I-119 Compound 11 (30.8 mg, 0.075 mmol) and 2-(methylsulfonyl)acetic acid (20.6 mg, 0.149 mmol) were dissolved in tetrahydrofuran (4 mL), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (56.8 mg, 0.149 mmol) and triethylamine (0.041 mL, 0.299 mmol) were added, and the mixture was stirred at room temperature for 2 hours. Water was added, and the mixture was extracted with ethyl acetate. After washing with water, the solvent was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform-methanol, amino silica gel) to obtain compound I-119 (35.4 mg, purity 97.0%, yield 88%). 1 H-NMR (DMSO-D6) δ: 10.07 (1H, s), 8.97 (1H, s), 8.56 (1H, d, J = 2.8 Hz), 7.89 (1H, dd, J = 8.8, 4.6 Hz), 7.77 (1H, td, J = 8.8, 2.8 Hz), 6.91 (1H, ddd, J = 11.0, 9.2, 2.2 Hz), 6.74-6.70 (1H, m), 4.76 (1H, d, J = 13.6 Hz), 4.71 (1H, d, J = 13.6 Hz), 4.39-4.19 (3H, m), 3.17 (3H, s), 2.25-2.19 (1H, m), 2.10-2.02 (1H, m). EXAMPLES

[0078] [ka] Step 1 Synthesis of compound 9 60% sodium hydride (314 mg, 7.86 mmol) was added to ethanol (20 mL) at 0°C, and after stirring for 10 minutes, known compound 12 (1.00 g, 7.15 mmol) and 88.3% ethyl diazoacetate (1.02 g, 7.86 mmol) were added dropwise and stirred at room temperature for 5 hours. 2 mol / L aqueous hydrochloric acid was added to the reaction solution at 0°C to adjust the pH to 8.6, and the solution was extracted with ethyl acetate. After washing with water, most of the solvent was distilled off under reduced pressure, and the solution was powdered with hexane-ethyl acetate to obtain compound 9 (1.49 g, 84% yield). 1 H-NMR (CDCl3) δ: 8.42 (1H, d, J = 3.0 Hz), 8.02 (1H, dd, J = 8.8, 4.5 Hz), 7.46 (1H, td, J = 8.5, 3.0 Hz), 5.66 (2H, br s), 4.42 (2H, q, J = 7.2 Hz), 1.43 (3H, t, J = 7.2 Hz).

[0079] The following compounds were synthesized in the same manner. The physical data of each compound are shown below. In the table, "RT" indicates the retention time (min) in LC / MS (liquid chromatography / mass spectrometry), "MS" indicates the mass (M+H) in LC / MS, and "LCMS Method" indicates one of the following measurement conditions for LC / MS. [Measurement condition A] Column: ACQUITY UPLC® BEH C18 (1.7 μm id2.1x50 mm) (Waters) Flow rate: 0.55 mL / min UV detection wavelength: 254 nm Mobile phase: [A] is an aqueous solution containing 0.1% formic acid, [B] is an acetonitrile solution containing 0.1% formic acid Gradient: A linear gradient of 5%-100% solvent [B] was performed over 3 minutes, and then 100% solvent [B] was maintained for 0.5 minutes. [Measurement condition B] Column: ACQUITY UPLC® BEH C18 (1.7 μm id2.1x50 mm) (Waters) Flow rate: 0.8 mL / min UV detection wavelength: 254 nm Mobile phase: [A] is an aqueous solution containing 0.1% formic acid, [B] is an acetonitrile solution containing 0.1% formic acid A linear gradient of 5%-100% solvent [B] was run over 3.5 min, followed by a 0.5 min hold at 100% solvent [B]. [Measurement conditions C] Column: ACQUITY UPLC® BEH C18 (1.7 μm id2.1x50 mm) (Waters) Flow rate: 0.8 mL / min UV detection wavelength: 254 nm Mobile phase: [A] is an aqueous solution containing 0.1% formic acid, [B] is an acetonitrile solution containing 0.1% formic acid A linear gradient of 5%-100% solvent [B] was run over 3.5 min, followed by a 0.5 min hold at 100% solvent [B]. [Measurement condition D] Column: Shim-pack XR-ODS (2.2μm id50x3.0mm) (Shimadzu) Flow rate: 1.6 mL / min UV detection wavelength: 254nm; Mobile phase: [A] is an aqueous solution containing 0.1% formic acid, [B] is an acetonitrile solution containing 0.1% formic acid Gradient: A linear gradient of 10%-100% solvent [B] was performed over 3 minutes, and then 100% solvent [B] was maintained for 0.5 minutes.

[0080] [Table 1]

[0081] [Table 2]

[0082]

Table 3

[0083]

Table 4

[0084]

Table 5

[0085]

Table 6

[0086]

Table 7

[0087]

Table 8

[0088]

Table 9

[0089]

Table 10

[0090]

Table 11

[0091]

Table 12

[0092]

Table 13

[0093]

Table 14

[0094]

Table 15

[0095]

Table 16

[0096]

Table 17

[0097]

Table 18

[0098]

Table 19

[0099]

Table 20

[0100]

Table 21

[0101]

Table 22

[0102] In addition, I-54 and I-55 have a mixture of R / S=1 / 1 asymmetric carbons in the parent nucleus. I-62 and I-63 have a single stereogenic core, but the absolute configuration has not been determined. I-72, I-105, I-106 and I-107 are stereoisomeric sulfoximines, but their absolute configurations have not yet been determined. I-73, I-108 and I-112 are mixed sulfoximines with R / S=1 / 1.

[0103] [Table 23]

[0104] Biological test examples of the compounds of the present invention are described below. The compound represented by formula (I) according to the present invention may be any compound as long as it has an inhibitory effect on MGAT2 and inhibits MGAT2. Specifically, in the evaluation method described below, IC50 is preferably 100 nM or less, more preferably 50 nM or less, and even more preferably 10 nM or less.

[0105] Preparation Example 1: Preparation of recombinant human MGAT2 The full-length human MGAT2 gene with a Flag tag added to the N-terminus was inserted into pFastBac (Invitrogen). According to the protocol of the Bac-to-Bac baculovirus expression system (Invitrogen), a recombinant baculovirus was prepared and used to infect Sf-9 cells. The collected cells were ultrasonically disrupted, and the membrane fraction was collected by centrifugation. Expression was confirmed by Western blot analysis using an anti-Flag antibody, and the recombinant human MGAT2 enzyme solution was obtained.

[0106] Test Example 1: Measurement of human MGAT2 inhibitory activity To a 384-well polystyrene microplate (Corning) into which 0.2 μL of a DMSO solution of each of the compounds of the present invention had been dispensed, 5 μL of an enzyme solution prepared in an assay buffer (100 mmol / L phosphate buffer (pH 7.4) containing 2 mmol / L DTT) and 5 μL of a substrate solution (100 mmol / L phosphate buffer (pH 7.4), 30 μmol / L 2-oleoylglycerol, 10 μmol / L oleoyl-CoA) were added, stirred and centrifuged, and then incubated in a humidified box at room temperature for 1 hour. After the enzyme reaction, the reaction was stopped by adding 50 μL of a stop solution (containing 0.2 μmol / L Diolein-d5, 0.4% formic acid and 50% isopropanol) containing an internal standard (IS), and the mixture was sealed on a Shimadzu GLC plate, stirred and centrifuged, and then measured by electrospray ionization using a RapidFire360 and an Agilent 6550 Q-TOF mass spectrometer. The reaction product (P) of the substrate 2-oleoylglycerol, the ammonium adduct ion of Diolein and IS, was detected, and the peak intensity ratio P / IS was calculated using the peak height to evaluate the inhibitory activity. The inhibitory activity was calculated using the following formula with and without the addition of enzyme as Control (+) / Control (-), the inhibition rate was set to 0% and 100%, respectively, and the peak intensity ratio P / IS when the compound of the invention was added was set as Sample, using TIBCO Spotfire (TIBCO Software). Inhibitory activity (%) = [1-{Sample-Control(-)} / {Control(+)-Control(-)}] * 100 The inhibitory activity results of each compound of the present invention are shown in the following table. 50 The nM indicates the concentration exhibiting 50% enzyme inhibition.

[0107] [Table 24]

[0108] Test Example 2: Metabolic stability test The compounds of the present invention were reacted with commercially available pooled human liver microsomes for a certain period of time, and the remaining ratios were calculated by comparing the reacted samples with unreacted samples to evaluate the extent to which the compounds of the present invention were metabolized in the liver.

[0109] In 0.2 mL of buffer solution (50 mmol / L Tris-HCl pH 7.4, 150 mmol / L potassium chloride, 10 mmol / L magnesium chloride) containing 0.5 mg protein / mL of human liver microsomes, the reaction was carried out in the presence of 1 mmol / L NADPH at 37°C for 0 or 30 minutes (oxidative reaction). After the reaction, 50 μL of the reaction solution was added to 100 μL of a methanol / acetonitrile = 1 / 1 (v / v) solution, mixed, and centrifuged at 3000 rpm for 15 minutes. The compound of the present invention in the centrifugal supernatant was quantified by LC / MS / MS, and the remaining amount of the compound of the present invention after the reaction was calculated by assuming the amount of the compound at 0 minutes of reaction as 100%. (Results) The residual rate at a compound concentration of 0.5 μmol / L is shown in the table below. Compound I-6: 92.4% Compound I-13: 76% Compound I-14: 103% Compound I-20: 74.5% Compound I-33: 98.5% Compound I-46: 78.1% Compound I-58: 88.4% Compound I-61: 95.6% Compound I-66: 105% Compound I-79: 77.2% Compound I-126: 100% Compound I-130: 94.8% Compound I-137: 101% Compound I-141: 99.4% Compound I-142: 106% Compound I-147: 89.8% Compound I-151: 104%

[0110] Test Example 3: Solubility test: The solubility of the compound of the present invention was determined under the condition of adding 1% DMSO. A 10 mmol / L compound solution was prepared in DMSO, and 6 μL of the compound solution of the present invention was added to 594 μL of pH 6.8 artificial intestinal fluid (250 mL of 0.2 mol / L potassium dihydrogen phosphate test solution, 118 mL of 0.2 mol / L NaOH test solution, and water were added to make 1000 mL). After standing at 25° C. for 16 hours, the mixture was filtered by suction. The filtrate was diluted 2-fold with methanol / water = 1 / 1 (V / V), and the concentration in the filtrate was measured using HPLC or LC / MS / MS by the absolute calibration curve method. The dilution concentration and dilution solvent were changed as necessary. (result) Compound I-6: >50 μmol / L Compound I-14: 41.8 μmol / L Compound I-46: >50 μmol / L Compound I-58: >50 μmol / L Compound I-66: >50 μmol / L Compound I-79: >50 μmol / L Compound I-126: >50 μmol / L Compound I-130: >50 μmol / L Compound I-137: >50 μmol / L Compound I-141: 48.9 μmol / L Compound I-142: >50 μmol / L Compound I-147: >50 μmol / L Compound I-151: >50 μmol / L

[0111] Test Example 4: Phototoxicity test As an in vitro phototoxicity test, a red blood cell photohemolysis test (Wolfgang JW Pepe et al., ATLA29, 145-162, 2001), which is an evaluation method using the effect on biological membranes and photoperoxidation as indicators, is performed. In this method, a mixture (concentration: 0.1-0.0008%) is used in which 2.5% (v / v) sheep red blood cell solution is added to a preparation solution of the compound of the present invention using dimethyl sulfoxide as a medium. Two microplates containing this mixture are prepared, and one microplate is irradiated with light (10 J / cm) in the UVA and UVB regions using an ultraviolet fluorescent lamp (GL20SE lamp, Sankyo Electric and FL20S-BLB lamp, Panasonic). 2 , 290-400 nm) and centrifuged together with the microplate that was not irradiated with light, and then the absorbance of the supernatant (540 nm or 630 nm) is measured. In order to determine the two indices (action on biomembranes and photoperoxidation) used to judge phototoxicity, the absorbance obtained from the compound of the present invention is subtracted from the absorbance in the medium for each of the cases of light irradiation and non-irradiation, and the value is used for the following calculations. Regarding the action on biomembranes, the photohemolysis rate is calculated from the difference in absorbance (540 nm) between the cases of light irradiation and non-irradiation, and regarding photoperoxidation, the change in absorbance (630 nm) between the cases of light irradiation and non-irradiation is calculated. In calculating the photohemolysis rate, the absorbance (540 nm) obtained from a 2.5% (v / v) sheep red blood cell solution that was forcibly hemolyzed using distilled water is used as the standard for the photohemolysis rate of 100%. When the photohemolysis rate is less than 10% and the change in absorbance at 630 nm is less than 0.05, it is rated as (-); when the photohemolysis rate is 10% or more and the change in absorbance at 630 nm is 0.05 or more, it is rated as (+).

[0112] Test Example 5: Cytotoxicity test The number of cells after exposure to the compound is automatically measured using a cell image analyzer, Toxinsight (Thermofisher Scientific), to evaluate the cytotoxicity of the compound of the present invention. HepG2 cells (derived from human liver cancer cells) are seeded in a 384-well plate at 60,000 cells / mL, and after 24 hours, a compound solution is added to each well. As the compound solution, a DMSO solution containing the compound of the present invention (maximum concentration is set to 50 μmol / L, and five-fold dilution is performed at a common ratio of 2 times, the lowest concentration is about 3.1 μmol / L), a solution of DMSO only as a negative control, and a camptothecin solution as a positive control are used. A DMSO solution of the compound of the present invention, a negative control solution, or a positive control solution is added to each well. After 71 hours, a Hoechst 33342 solution diluted with Dulbecco's phosphate buffer solution (D-PBS) to a final concentration of 1 μg / mL is added to each well, and the nuclei are stained for 1 hour in a 37°C, 5% CO2 incubator. After staining, the cells are fixed with 4% paraformaldehyde for 20 minutes in a 37°C CO2 incubator. Finally, after washing three times with D-PBS, the number of fluorescently colored nuclei per well is counted using Toxinsight (Thermofisher Scientific). Four wells are set up per concentration, and the average number of nuclei (number of cells in which no damage was observed) in the four wells and the variance (SD) are calculated. The compound exposure concentration at which the average value is reduced by 50% or more from the average value of the negative control group (IC 50 ) is calculated. 50 The smaller the value, the higher the risk of cytotoxicity.

[0113] Test Example 6: Anti-obesity effect test The anti-obesity effect of the compounds of the Examples was examined in C57BL / 6j mice (DIO mice) fed a high-fat diet (TestDiet; 58Y1). Five-week-old male C57BL / 6j (Japan CLEA) mice were purchased and kept for 4 weeks under a 12-hour light-dark cycle with a high-fat diet to create DIO mice. Three weeks before compound administration, the vehicle (0.5% HPMC) was administered twice a day. Randomization was performed based on changes in body weight and food intake during the habituation administration period, and groups were divided (n=7). From day 1 to day 28, the example compound or vehicle (0.5% HPMC) was administered by gavage twice a day. Body weight and food intake were measured every day. On day 28, the mice were dissected, and epididymal fat weight was measured, and biochemical tests were performed on the collected blood.

[0114] Test Example 7: CYP Inhibition Test Using commercially available pooled human liver microsomes, the following typical substrate metabolic reactions of major human CYP5 molecular species (CYP1A2, 2C9, 2C19, 2D6, 3A4) were used as indicators to evaluate the degree to which the production of each metabolite was inhibited by the compound of the present invention: O-deethylation of 7-ethoxyresorufin (CYP1A2), methyl-hydroxylation of tolbutamide (CYP2C9), 4'-hydroxylation of mephenytoin (CYP2C19), O-demethylation of dextromethorphan (CYP2D6), and hydroxylation of terfenadine (CYP3A4). The reaction conditions were as follows: substrate, 0.5 μmol / L ethoxyresorufin (CYP1A2), 100 μmol / L tolbutamide (CYP2C9), 50 μmol / L S-mephenytoin (CYP2C19), 5 μmol / L dextromethorphan (CYP2D6), 1 μmol / L terfenadine (CYP3A4); reaction time, 15 minutes; reaction temperature, 37°C; enzyme, pooled human liver microsome, 0.2 mg protein / mL; concentration of the compound of the present invention, 1, 5, 10, 20 μmol / L (4 points). The reaction solution was prepared by adding five kinds of substrates, human liver microsomes, and the compound of the present invention in 50 mmol / L Hepes buffer in a 96-well plate in the above composition, and adding NADPH as a coenzyme to start the metabolic reaction as an indicator. After reacting at 37°C for 15 minutes, the reaction was stopped by adding a methanol / acetonitrile = 1 / 1 (V / V) solution. After centrifugation at 3000 rpm for 15 minutes, resorufin (CYP1A2 metabolite) in the centrifugal supernatant was quantified by a fluorescent multi-label counter or LC / MS / MS, and tolbutamide hydroxylated form (CYP2C9 metabolite), mephenytoin 4' hydroxylated form (CYP2C19 metabolite), dextrorphan (CYP2D6 metabolite), and terfenadine alcohol form (CYP3A4 metabolite) were quantified by LC / MS / MS. The control (100%) was a reaction system in which only DMSO, the solvent in which the drug was dissolved, was added. The remaining activity (%) was calculated, and the IC was calculated by inverse estimation using a logistic model based on the concentration and inhibition rate. 50 was calculated. (result) Compound I-6: 5 types >20μmol / L Compound I-14: 5 types >20μmol / L Compound I-20: 5 types >20μmol / L Compound I-33: 5 species >20μmol / L Compound I-46: 5 species >20μmol / L Compound I-58: 5 types >20μmol / L Compound I-66: 5 types >20μmol / L Compound I-126: 5 types >20μmol / L Compound I-130: 5 species >20μmol / L Compound I-141: 5 species >20μmol / L Compound I-142: 5 types >20μmol / L Compound I-147: 5 types >20μmol / L Compound I-151: 5 species >20μmol / L

[0115] Test Example 8: BA Test Materials and methods for oral absorption study (1) Animals used: Mice or SD rats were used. (2) Rearing conditions: Mice or SD rats were allowed free access to solid food and sterilized tap water. (3) Dosage and grouping: Oral and intravenous administration was performed at the specified dose. The groups were set up as follows. (Dosages were changed for each compound.) Oral administration: 1-30mg / kg (n=2-3) Intravenous administration: 0.5-10mg / kg (n=2-3) (4) Preparation of administration solution: Oral administration was performed as a solution or suspension, while intravenous administration was performed as a solubilized solution. (5) Method of administration: Oral administration was performed by forcibly administering the compound into the stomach using an oral tube, while intravenous administration was performed through the tail vein or femoral vein using a syringe with an injection needle. (6) Evaluation item: Blood samples were collected over time, and the plasma concentration of the compound of the present invention was measured using LC / MS / MS. (7) Statistical analysis: The area under the plasma concentration-time curve (AUC) of the compound of the present invention was calculated using the nonlinear least squares program WinNonlin (registered trademark) for the plasma concentration-time transition of the compound of the present invention. The bioavailability (BA) of the compound of the present invention was calculated from the AUC of the oral administration group and the intravenous administration group. (result) Compound I-6:55.1% Compound I-20:63.4% Compound I-33:60.5% Compound I-46:53.1% Compound I-58:88.2% Compound I-137:49% Compound I-141:67% Compound I-142:66.2%

[0116] Study Example 9: CYP3A4(MDZ)MBI Study This is a test to evaluate the mechanism based inhibition (MBI) ability of the compound of the present invention from the enhancement by metabolic reaction regarding CYP3A4 inhibition. CYP3A4 inhibition was evaluated using pooled human liver microsomes and the 1-hydroxylation reaction of midazolam (MDZ) as an indicator. The reaction conditions were as follows: substrate, 10 μmol / L MDZ; pre-reaction time, 0 or 30 minutes; reaction time, 2 minutes; reaction temperature, 37°C; pooled human liver microsomes, 0.5 mg / mL during pre-reaction and 0.05 mg / mL (10-fold dilution) during reaction; concentration of the compound of the present invention during pre-reaction, 1, 5, 10, and 20 μmol / L (4 points). Pooled human liver microsomes and the compound of the present invention were added to a 96-well plate as a pre-reaction solution in K-Pi buffer (pH 7.4) with the above pre-reaction composition, and a portion of the solution was transferred to another 96-well plate so as to be diluted 1 / 10 with substrate and K-Pi buffer, and a coenzyme, NADPH, was added to start the reaction using the indicator (no pre-reaction). After a predetermined reaction time, the reaction was stopped by adding a methanol / acetonitrile = 1 / 1 (V / V) solution. NADPH was also added to the remaining pre-reaction solution to start the pre-reaction (with pre-reaction). After a predetermined reaction time, a portion of the solution was transferred to another plate so as to be diluted 1 / 10 with substrate and K-Pi buffer, and a reaction using the indicator was started. After a predetermined reaction time, the reaction was stopped by adding a methanol / acetonitrile = 1 / 1 (V / V) solution. After centrifuging the plates in which each indicator reaction was performed at 3000 rpm for 15 minutes, 1-hydroxymidazolam in the centrifugal supernatant was quantified by LC / MS / MS. The reaction system was treated as a control (100%) with only DMSO, the solvent in which the compound of the present invention was dissolved, and the remaining activity (%) was calculated when the compound of the present invention was added at each concentration. The IC was calculated by inverse estimation using a logistic model using the concentration and inhibition rate. The IC at 0 min preincubation / IC at 30 min preincubation was used as the shifted IC value, and if the shifted IC was 1.5 or more, it was considered positive, and if the shifted IC was 1.0 or less, it was considered negative. (result) Compound I-6:Negative Compound I-14:Negative Compound I-20:Negative Compound I-46:Negative Compound I-58:Negative Compound I-66:Negative Compound I-126:Negative Compound I-130:Negative Compound I-147:Negative Compound I-151:Negative

[0117] Test Example 10: Powder solubility test An appropriate amount of the compound of the present invention was placed in an appropriate container, and 200 μL of JP-1 solution (2.0 g of sodium chloride, 7.0 mL of hydrochloric acid, and water to make 1000 mL), JP-2 solution (500 mL of phosphate buffer at pH 6.8 and 500 mL of water) and 20 mmol / L sodium taurocholate (TCA) / JP-2 solution (1.08 g of TCA and JP-2 solution to make 100 mL) were added to each container. If the entire amount was dissolved after the addition of the test solution, the compound of the present invention was appropriately added. The container was sealed and shaken at 37°C for 1 hour, and then filtered. 100 μL of methanol was added to 100 μL of each filtrate to perform 2-fold dilution. The dilution ratio and dilution solvent were changed as necessary. The container was checked for the presence of bubbles and precipitates, and then sealed and shaken. The compound of the present invention was quantified using HPLC by the absolute calibration curve method. Compound I-46:JP-2 solution 8.64 μmol / L

[0118] Test Example 11: Fluctuation Ames Test The mutagenicity of the compounds of the present invention was evaluated. 20μL of frozen Salmonella typhimurium (TA98 strain, TA100 strain) was inoculated into 10mL of liquid nutrient medium (2.5% Oxoid nutrient broth No.2) and pre-cultured with shaking at 37℃ for 10 hours. For the TA98 strain, 8.0mL of the bacterial solution was centrifuged (2000×g, 10 minutes) to remove the culture medium. The bacteria were suspended in 8.0mL of Micro F buffer (K2HPO4: 3.5g / L, KH2PO4: 1g / L, (NH4)2SO4: 1g / L, trisodium citrate dihydrate: 0.25g / L, MgSO4·7H20: 0.1g / L) and added to 120mL of Exposure medium (MicroF buffer containing biotin: 8μg / mL, histidine: 0.2μg / mL, glucose: 8mg / mL). For the TA100 strain, 3.1mL of the bacterial solution was added to 120mL of Exposure medium to prepare the test bacterial solution. The compound of the present invention DMSO solution (diluted in several steps at a common ratio of 2 to 3 times from the maximum dose of 50 mg / mL), DMSO as a negative control, 50 μg / mL 4-nitroquinoline-1-oxide DMSO solution for the TA98 strain as a positive control under non-metabolic activation conditions, 0.25 μg / mL 2- (2-furyl) -3- (5-nitro-2-furyl) acrylamide DMSO solution for the TA100 strain as a positive control, 40 μg / mL 2-aminoanthracene DMSO solution for the TA98 strain under metabolic activation conditions, and 20 μg / mL 2-aminoanthracene DMSO solution for the TA100 strain were mixed with 12 μL each and 588 μL of the test bacteria solution (a mixture of 498 μL of the test bacteria solution and 90 μL of S9 mix under metabolic activation conditions), and cultured with shaking at 37 ° C. for 90 minutes. 230 μL of the bacterial solution exposed to the compound of the present invention was mixed with 1150 μL of indicator medium (MicroF buffer containing biotin: 8 μg / mL, histidine: 0.2 μg / mL, glucose: 8 mg / mL, bromocresol purple: 37.5 μg / mL), and 50 μL was dispensed into 48 wells of a microplate per dose, and statically cultured for 3 days at 37° C. Wells containing bacteria that have acquired the ability to grow due to a mutation in the amino acid (histidine) synthase gene changed color from purple to yellow due to a pH change, so the number of wells with bacterial growth that had changed color to yellow in 48 wells per dose was counted and evaluated in comparison with the negative control group.Mutagenicity is indicated as negative (-) and positive (+). Compound I-33:(-)

[0119] Test Example 12: hERG Test To evaluate the risk of electrocardiogram QT interval prolongation by the compounds of the present invention, we used CHO cells expressing the human ether-a-go-go related gene (hERG) channel to investigate the delayed rectifier K channel, which plays an important role in the ventricular repolarization process. + Current (I Kr The effect of the compound of the present invention on Using a fully automated patch clamp system (QPatch; Sophion Bioscience A / S), the whole-cell patch clamp technique was used to hold the cells at a membrane potential of -80 mV, apply a leak potential of -50 mV, and then apply a depolarizing stimulus of +20 mV for 2 seconds, followed by a repolarizing stimulus of -50 mV for 2 seconds. The I Kr After the generated current became stable, an extracellular solution containing the compound of the present invention dissolved at a desired concentration (NaCl: 145 mmol / L, KCl: 4 mmol / L, CaCl2: 2 mmol / L, MgCl2: 1 mmol / L, glucose: 10 mmol / L, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid): 10 mmol / L, pH = 7.4) was applied to the cells at room temperature for 10 minutes. The obtained I Kr The absolute value of the maximum tail current was measured using analysis software (Falster Patch; Sophion Bioscience A / S) based on the current value at the resting membrane potential. Furthermore, the inhibition rate relative to the maximum tail current before application of the compound of the present invention was calculated, and the I Kr The impact on was evaluated. (Results) The inhibition rate at a compound concentration of 10 μmol / L is shown. Compound I-20:27.8% Compound I-33:21.3% Compound I-66:14.6% Compound I-79:25.5% Compound I-14:25.5% Compound I-126:14.2% Compound I-130: 15.4% Compound I-137:23.6% Compound I-141:14.0% Compound I-142:10.6% Compound I-147:21.6% Compound I-151:25.8%

[0120] Test Example 13 (Solution Stability Test) 0.4 mg of the compound of the present invention was weighed into a 4 mL screw vial, and 2 mL of each of various media pH = 1 (0.1N HClaq. + 30% MeCN), pH = 7 (pH 7 phosphate buffer (100 mM + 30% MeCN), pH = 9 (pH 9 carbonate buffer (100 mM + 30% MeCN) was added. Complete dissolution was confirmed. If not dissolved, filtration was performed with a 0.45 μm filter. The solution or filtrate was placed in an HPLC vial. The HPLC sample cooler was set to 40 ° C., and a sequence was set up so that sampling was performed by HPLC at 0, 3, 6, 9, 12, 15, and 18 hours. The area value of the 0 hr sample was set as 100%, and stability over time was evaluated. (result) Compound I-3 Residual rate at 40℃ for 18hr: pH=1 100.2%, pH=7 100.9%, pH=9 100.2%

[0121] Formulation examples The compound of the present invention can be administered as a pharmaceutical composition by any conventional route, in particular enterally, e.g., orally, e.g., in the form of tablets or capsules, or parenterally, e.g., in the form of injection solutions or suspensions, topically, e.g., in the form of lotions, gels, ointments or creams, or in the form of nasal or suppositories. Pharmaceutical compositions containing the compound of the present invention in free form or in the form of a pharma-ceutically acceptable salt together with at least one pharma-ceutically acceptable carrier or diluent can be prepared by conventional mixing, granulation or coating methods. For example, oral compositions can be tablets, granules, or capsules containing excipients, disintegrants, binders, lubricants, etc., and active ingredients, etc. In addition, injectable compositions can be solutions or suspensions, which may be sterilized and may contain preservatives, stabilizers, buffers, etc. [Industrial Applicability]

[0122] Since the compound of the present invention has an MGAT2 inhibitory effect, it is useful as a medicine for diseases in which MGAT2 is involved, such as obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, hyperfatty acidemia, diabetes, and arteriosclerosis.

Claims

1. Formula (I): 【Chemistry 1】 (In the formula, R 1 is hydrogen, hydroxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted substituted or unsubstituted non-aromatic heterocycle carbonyl, substituted or unsubstituted aromatic carbocycle oxycarbonyl, substituted or unsubstituted non-aromatic carbocycle oxycarbonyl, substituted or unsubstituted aromatic heterocycle oxycarbonyl, substituted or unsubstituted non-aromatic heterocycle oxycarbonyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, or substituted or unsubstituted non-aromatic heterocycle sulfonyl; R 2a and R 2b together with the adjacent carbon atom form ring B, Ring B is of the formula: 【Chemistry 2】 (In the formula, B 3 is CR 13a R 13b , N.R. 13c , O or S; B 4 is CR 14a R 14b , N.R. 14c , O or S; B 5 is CR 15a R 15b , N.R. 15c , O or S; R 13a , R 14a , and R 15a each independently represents hydrogen, halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbo nyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocycle-oxy, substituted or unsubstituted non-aromatic carbocycle-oxy, substituted or unsubstituted aromatic heterocycle-oxy, substituted or unsubstituted non-aromatic heterocycle-oxy, substituted or unsubstituted aromatic carbocycle-carbonyloxy, substituted or unsubstituted non-aromatic carbocycle-carbonyloxy, substituted or unsubstituted aromatic heterocycle-carbonyloxy, substituted or unsubstituted non-aromatic heterocycle ring carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl,Substituted or unsubstituted aromatic heterocycle sulfanyl, substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -L-N=S(=O)(-R, S1 )-R S2 , formula: -LS(=O)(=NR N )-R S1 , formula: -N=S(=NR N ) (-R S1 )-R S2 or the formula: -S(=N-R N ) 2 -R S1 is a group represented by R 13b , R 14b , and R 15b each independently represents hydrogen, halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbo nyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocycle-oxy, substituted or unsubstituted non-aromatic carbocycle-oxy, substituted or unsubstituted aromatic heterocycle-oxy, substituted or unsubstituted non-aromatic heterocycle-oxy, substituted or unsubstituted aromatic carbocycle-carbonyloxy, substituted or unsubstituted non-aromatic carbocycle-carbonyloxy, substituted or unsubstituted aromatic heterocycle-carbonyloxy, substituted or unsubstituted non-aromatic heterocycle ring carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl,Substituted or unsubstituted aromatic heterocycle sulfanyl, substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -L-N=S(=O)(-R, S1 )-R S2 , formula: -LS(=O)(=NR N )-R S1 , formula: -N=S(=NR N ) (-R S1 )-R S2 or the formula: -S(=N-R N ) 2 -R S1 is a group represented by R 13c , R 14c , and R 15c each independently represents hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkene, nylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic groups, substituted or unsubstituted non-aromatic carbocyclic groups, substituted or unsubstituted aromatic heterocyclic groups, substituted or unsubstituted substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocycle-oxy, substituted or unsubstituted non-aromatic carbocycle-oxy, substituted or unsubstituted aromatic heterocycle-oxy, substituted or unsubstituted non-aromatic heterocycle-oxy, substituted or unsubstituted aromatic carbocycle-carbonyl, substituted or unsubstituted non-aromatic carbocycle-carbonyl, substituted or unsubstituted aromatic heterocycle-carbonyl, substituted or unsubstituted non-aromatic heterocycle-carbonyl, substituted or unsubstituted aromatic carbocycle-oxycarbonyl, substituted or unsubstituted non-aromatic carbocycle-oxycarbonyl, substituted or unsubstituted aromatic heterocycle-oxycarbonyl, substituted or unsubstituted non-aromatic heterocycle-oxycarbonyl, substituted or unsubstituted aromatic carbocycle-sulfanyl, substituted or unsubstituted non-aromatic carbocycle-sulfanyl, substituted or unsubstituted aromatic heterocycle-sulfanyl, substituted or unsubstituted non-aromatic heterocycle-sulfanyl, substituted or unsubstituted aromatic carbocycle-sulfinyl, substituted or unsubstituted non-aromatic carbocycle-sulfinyl, substituted or unsubstituted aromatic heterocycle-sulfinyl, substituted or unsubstituted non-aromatic heterocycle-sulfinyl, substituted or unsubstituted aromatic carbocycle-sulfonyl,a substituted or unsubstituted non-aromatic carbocyclic sulfonyl, a substituted or unsubstituted aromatic heterocyclic sulfonyl, or a substituted or unsubstituted non-aromatic heterocyclic sulfonyl; R 6 each independently represents halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyl, Oxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, is an unsubstituted aromatic carbocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted aromatic carbocycle-oxy, a substituted or unsubstituted non-aromatic carbocycle-oxy, a substituted or unsubstituted aromatic heterocycle-oxy, a substituted or unsubstituted non-aromatic heterocycle-oxy, a substituted or unsubstituted aromatic carbocycle-carbonyloxy, a substituted or unsubstituted non-aromatic carbocycle-carbonyloxy, a substituted or unsubstituted aromatic heterocycle-carbonyloxy, a substituted or unsubstituted non-aromatic heterocycle carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl,Substituted or unsubstituted aromatic heterocycle sulfanyl, substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -L-N=S(=O)(-R, S1 )-R S2 , formula: -LS(=O)(=NR N )-R S1 , formula: -N=S(=NR N ) (-R S1 )-R S2 or the formula: -S(=N-R N ) 2 -R S1 and n is an integer from 1 to 4; R 3a is hydrogen, R 3b is hydrogen; R 4a is the formula: 【Chemistry 3】 and L 3 is a single bond or a substituted or unsubstituted alkylene; R 7 is hydrogen, halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbo nyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic ring-oxy, substituted or unsubstituted non-aromatic carbocyclic ring-oxy, substituted or unsubstituted aromatic heterocyclic ring-oxy, substituted or unsubstituted non-aromatic heterocyclic ring-oxy, substituted or unsubstituted aromatic carbocyclic ring-carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic ring-carbonyloxy, substituted or unsubstituted aromatic heterocyclic ring-carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic ring-carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl, substituted or unsubstituted aromatic heterocyclic sulfanyl,Substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -L-N=S(=O)(-R, S1 )-R S2 , formula: -LS(=O)(=NR N )-R S1 , formula: -N=S(=NR N ) (-R S1 )-R S2 or the formula: -S(=N-R N ) 2 -R S1 is a group represented by However, L 3 When is a single bond, R 7 is not hydrogen or a halogen, R 4b is halogen, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkene, nylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic groups, substituted or unsubstituted is an unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted aromatic carbocyclic ring-oxy, a substituted or unsubstituted non-aromatic carbocyclic ring-oxy, a substituted or unsubstituted aromatic heterocyclic ring-oxy, a substituted or unsubstituted non-aromatic heterocyclic ring-oxy, a substituted or unsubstituted aromatic carbocyclic ring-carbonyloxy, a substituted or unsubstituted non-aromatic carbocyclic ring-carbonyloxy, a substituted or unsubstituted aromatic heterocyclic ring-carbonyloxy, a substituted or unsubstituted non-aromatic heterocyclic ring-carbonyloxy, a substituted or unsubstituted aromatic aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfanyl, substituted or unsubstituted non-aromatic carbocyclic sulfanyl, substituted or unsubstituted aromatic heterocyclic sulfanyl,Substituted or unsubstituted non-aromatic heterocycle sulfanyl, substituted or unsubstituted aromatic carbocycle sulfinyl, substituted or unsubstituted non-aromatic carbocycle sulfinyl, substituted or unsubstituted aromatic heterocycle sulfinyl, substituted or unsubstituted non-aromatic heterocycle sulfinyl, substituted or unsubstituted aromatic carbocycle sulfonyl, substituted or unsubstituted non-aromatic carbocycle sulfonyl, substituted or unsubstituted aromatic heterocycle sulfonyl, substituted or unsubstituted non-aromatic heterocycle sulfonyl, the formula: -L-N=S(=O)(-R, S1 )-R S2 , formula: -LS(=O)(=NR N )-R S1 , formula: -N=S(=NR N ) (-R S1 )-R S2 or the formula: -S(=N-R N ) 2 -R S1 is a group represented by Each L is independently a single bond, alkylene, or C(=O); R S1 and R S2 are each independently hydrogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted aromatic carbocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted non-aromatic heterocyclic group; or R bonded to the same sulfur atom S1 and R S2 may be combined with the sulfur atom to form a substituted or unsubstituted non-aromatic heterocycle; R N are each independently hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, or substituted or unsubstituted non-aromatic heterocyclic carbonyl), or a pharma- ceutically acceptable salt thereof.

2. The compound according to claim 1, wherein ring B is represented by any one of the following formulas, or a pharma- ceutically acceptable salt thereof. formula: 【Chemistry 4】 (In the formula, R 6 , R 13a , R 13b , R 14a , R 14b , R 15a , R 15b and n are as defined in claim 1.

3. R 6 3. The compound according to claim 1 or 2, wherein each of the radicals is independently halogen, cyano, hydroxy, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted non-aromatic carbocyclic oxy, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted non-aromatic carbocyclic sulfonyl, or substituted or unsubstituted non-aromatic heterocyclic sulfonyl, or a pharma-ceutically acceptable salt thereof.

4. R 6 The compound according to any one of claims 1 to 3, wherein each is independently halogen, or substituted or unsubstituted alkyloxy, or a pharma- ceutically acceptable salt thereof.

5. The compound according to any one of claims 1 to 4, wherein ring B is represented by any one of the following formulas, or a pharma- ceutically acceptable salt thereof. formula: 【Chemistry 5】 (In the formula, R 6 are each independently substituted or unsubstituted alkyloxy; R 13a , R 13b , R 14a , R 14b , R 15a , and R 15b has the same meaning as in claim 1)

6. The compound according to any one of claims 1 to 4, wherein ring B is represented by any one of the following formulas, or a pharma- ceutically acceptable salt thereof. formula: 【Chemistry 6】 (In the formula, R 6 are each independently a halogen or a substituted or unsubstituted alkyloxy; R 13a , R 13b , R 14a , R 14b , R 15a , and R 15b has the same meaning as in claim 1)

7. L 3 is a substituted or unsubstituted alkylene; R 7 is halogen, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, or a group represented by the formula: -L-S(=O)(=N-R N )-R S1 7. The compound according to claim 1, wherein:

8. L 3 is a single bond, R 7 The compound according to any one of claims 1 to 6, wherein is a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted non-aromatic heterocyclic group, or a pharma- ceutically acceptable salt thereof.

9. R 4b The compound according to any one of claims 1 to 8, wherein is a substituted or unsubstituted alkyl, a substituted or unsubstituted aromatic carbocyclic group, or a substituted or unsubstituted aromatic heterocyclic group, or a pharma- ceutically acceptable salt thereof.

10. R 1 is hydrogen, R S1 and R S2 are each independently hydrogen or substituted or unsubstituted alkyl; and R N The compound according to any one of claims 1 to 9, wherein each is independently hydrogen, or substituted or unsubstituted alkyl, or a pharma- ceutically acceptable salt thereof.

11. R 1 is hydrogen, Ring B is of the formula: 【Chemistry 7】 and R 6 are each independently halogen, alkyloxy or haloalkyloxy; n is 1 or 2; L 3 is alkylene or alkylene substituted with halogen; R 7 is halogen or alkylsulfonyl, R 4b is a substituted or unsubstituted phenyl group or a substituted or unsubstituted 6-membered aromatic heterocyclic group; Here, R 4b When is substituted, the substituents are one or more groups selected from the group consisting of halogen, cyano, alkyl, haloalkyl, and cyclopropanyl; 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof.

12. Compounds I-6, I-13, I-14, I-20, I-33, I-46, I-58, I- 61, I-66, I-79, I-123, I-124, I-126, I-130, I-1 33, I-136, I-137, I-139, I-141, I-142, I-143, I -145, I-147, I-151 and I-153: 【Chemistry 8】 【Chemistry 9】 【Chemistry 10】 A compound selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

13. A compound selected from the group consisting of the following compounds, or a pharma- ceutically acceptable salt thereof: 【Chemistry 11】

14. A compound selected from the group consisting of the following compounds, or a pharma- ceutically acceptable salt thereof: 【Chemistry 12】

15. A compound represented by the following formula: or a pharma- ceutically acceptable salt thereof. 【Chemistry 13】

16. A compound represented by the following formula: or a pharma- ceutically acceptable salt thereof. 【Chemistry 14】

17. A compound represented by the following formula: or a pharma- ceutically acceptable salt thereof. 【Chemistry 15】

18. A compound represented by the following formula: or a pharma- ceutically acceptable salt thereof. 【Chemistry 16】

19. A compound represented by the following formula: or a pharma- ceutically acceptable salt thereof. 【Chemistry 17】

20. A compound represented by the following formula: or a pharma- ceutically acceptable salt thereof. 【Chemistry 18】

Images